{
    "abstract": " The anticancer drug ellipticine exerts its genotoxic effects after metabolic activation by cytochrome P450 (CYP) enzymes. The present study has examined the role of cytochrome P450 oxidoreductase (POR) and cytochrome b 5 (Cyb5), electron donors to P450 enzymes, in the CYP-mediated metabolism and disposition of ellipticine in vivo. We used Hepatic Reductase Null (HRN) and Hepatic Cytochrome b 5 /P450 Reductase Null (HBRN) mice. HRN mice have POR deleted specifically in hepatocytes; HBRN mice also have Cyb5 deleted in the liver. Mice were treated once with 10 mg/kg body weight ellipticine (n = 4/group) for 24 h. Ellipticine-DNA adduct levels measured by 32 P-postlabelling were significantly lower in HRN and HBRN livers than in wild-type (WT) livers; however no significant difference was observed between HRN and HBRN livers. Ellipticine-DNA adduct formation in WT, HRN and HBRN livers correlated with Cyp1a and Cyp3a enzyme activities measured in hepatic microsomes in the presence of NADPH confirming the importance of P450 enzymes in the bioactivation of ellipticine in vivo. Hepatic microsomal fractions were also utilised in incubations with ellipticine and DNA in the presence of NADPH, cofactor for POR, and NADH, cofactor for Cyb5 reductase (Cyb5R), to examine ellipticine-DNA adduct formation. With NADPH adduct formation decreased as electron donors were lost which correlated with the formation of the reactive metabolites 12- and 13-hydroxy-ellipticine in hepatic microsomes. No difference in adduct formation was observed in the presence of NADH. Our study demonstrates that Cyb5 contributes to the P450-mediated bioactivation of ellipticine in vitro, but not in vivo. ",
    "author_highlights": [
        {
            "endOffset": 16009,
            "sentence": "The anticancer drug ellipticine is activated by cytochrome P450 (CYP) enzymes.",
            "startOffset": 15931
        },
        {
            "endOffset": 16095,
            "sentence": "Cytochrome b5 (Cyb5) and NADPH:CYP oxidoreductase (POR) modulate CYP enzyme activity.",
            "startOffset": 16010
        },
        {
            "endOffset": 16196,
            "sentence": "Ellipticine bioactivation was investigated in mouse lines with hepatic deletions of Cyb5 and/or POR.",
            "startOffset": 16096
        },
        {
            "endOffset": 16259,
            "sentence": "POR strongly contributed to ellipticine bioactivation in vivo.",
            "startOffset": 16197
        },
        {
            "endOffset": 16359,
            "sentence": "Cyb5 contributed little to ellipticine bioactivation in vivo contrasting previous in vitro studies.",
            "startOffset": 16260
        }
    ],
    "bib_entries": {
        "bb0005": {
            "authors": [
                {
                    "first": "Dagmar",
                    "initial": "D.",
                    "last": "Aimov\u00e1"
                },
                {
                    "first": "Jitka",
                    "initial": "J.",
                    "last": "Poljakov\u00e1"
                },
                {
                    "first": "V\u011bra",
                    "initial": "V.",
                    "last": "Kotrbov\u00e1"
                },
                {
                    "first": "Michaela",
                    "initial": "M.",
                    "last": "Moserov\u00e1"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                },
                {
                    "first": "Volker M.",
                    "initial": "V.M.",
                    "last": "Arlt"
                }
            ],
            "doi": "10.2478/v10102-010-0033-z",
            "firstpage": "160",
            "issn": "13376853",
            "lastpage": "168",
            "pub_year": 2008,
            "title": "Ellipticine and benzo(a)pyrene increase their own metabolic activation via modulation of expression and enzymatic activity of cytochromes P450 1A1 and 1A2",
            "volume": "1"
        },
        "bb0010": {
            "authors": [
                {
                    "first": "Dagmar",
                    "initial": "D.",
                    "last": "Aimov\u00e1"
                },
                {
                    "first": "Lucie",
                    "initial": "L.",
                    "last": "Svobodov\u00e1"
                },
                {
                    "first": "V\u011bra",
                    "initial": "V.",
                    "last": "Kotrbov\u00e1"
                },
                {
                    "first": "Barbora",
                    "initial": "B.",
                    "last": "Mr\u00e1zov\u00e1"
                },
                {
                    "first": "Petr",
                    "initial": "P.",
                    "last": "Hodek"
                },
                {
                    "first": "Ji\u0159\u00ed",
                    "initial": "J.",
                    "last": "Hude\u010dek"
                },
                {
                    "first": "Radka",
                    "initial": "R.",
                    "last": "V\u00e1clav\u00edkov\u00e1"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                }
            ],
            "doi": "10.1124/dmd.107.016048",
            "firstpage": "1926",
            "issn": "00909556",
            "lastpage": "1934",
            "pmid": "17656468",
            "pub_year": 2007,
            "title": "The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism",
            "volume": "35"
        },
        "bb0015": {
            "authors": [
                {
                    "first": "Volker M.",
                    "initial": "V.M.",
                    "last": "Arlt"
                },
                {
                    "first": "Colin J.",
                    "initial": "C.J.",
                    "last": "Henderson"
                },
                {
                    "first": "C. Roland",
                    "initial": "C.R.",
                    "last": "Wolf"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                },
                {
                    "first": "David H.",
                    "initial": "D.H.",
                    "last": "Phillips"
                }
            ],
            "doi": "10.1039/c4tx00116h",
            "firstpage": "548",
            "issn": "2045452X",
            "lastpage": "562",
            "pub_year": 2015,
            "title": "The Hepatic Reductase Null (HRN\u2122) and Reductase Conditional Null (RCN) mouse models as suitable tools to study metabolism, toxicity and carcinogenicity of environmental pollutants",
            "volume": "4"
        },
        "bb0020": {
            "authors": [
                {
                    "first": "Volker M.",
                    "initial": "V.M.",
                    "last": "Arlt"
                },
                {
                    "first": "Miriam C.",
                    "initial": "M.C.",
                    "last": "Poirier"
                },
                {
                    "first": "Sarah E.",
                    "initial": "S.E.",
                    "last": "Sykes"
                },
                {
                    "first": "Kaarthik",
                    "initial": "K.",
                    "last": "John"
                },
                {
                    "first": "Michaela",
                    "initial": "M.",
                    "last": "Moserova"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborova"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Roland Wolf"
                },
                {
                    "first": "Colin J.",
                    "initial": "C.J.",
                    "last": "Henderson"
                },
                {
                    "first": "David H.",
                    "initial": "D.H.",
                    "last": "Phillips"
                }
            ],
            "doi": "10.1016/j.toxlet.2012.06.016",
            "firstpage": "160",
            "issn": "03784274",
            "lastpage": "166",
            "pmid": "22759596",
            "pub_year": 2012,
            "title": "Exposure to benzo[a]pyrene of Hepatic Cytochrome P450 Reductase Null (HRN) and P450 Reductase Conditional Null (RCN) mice: Detection of benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and 32P-postlabelling",
            "volume": "213"
        },
        "bb0025": {
            "authors": [
                {
                    "first": "Volker M.",
                    "initial": "V.M.",
                    "last": "Arlt"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborova"
                },
                {
                    "first": "Colin J.",
                    "initial": "C.J.",
                    "last": "Henderson"
                },
                {
                    "first": "Martin R.",
                    "initial": "M.R.",
                    "last": "Osborne"
                },
                {
                    "first": "Christian A.",
                    "initial": "C.A.",
                    "last": "Bieler"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                },
                {
                    "first": "Vaclav",
                    "initial": "V.",
                    "last": "Martinek"
                },
                {
                    "first": "Bruno",
                    "initial": "B.",
                    "last": "Sopko"
                },
                {
                    "first": "C. Roland",
                    "initial": "C.R.",
                    "last": "Wolf"
                },
                {
                    "first": "Heinz H.",
                    "initial": "H.H.",
                    "last": "Schmeiser"
                },
                {
                    "first": "David H.",
                    "initial": "D.H.",
                    "last": "Phillips"
                }
            ],
            "doi": "10.1158/0008-5472.CAN-04-3544",
            "firstpage": "2644",
            "issn": "00085472",
            "lastpage": "2652",
            "pmid": "15805261",
            "pub_year": 2005,
            "title": "Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltranferases and sulfotransferases in human hepatic cytosols",
            "volume": "65"
        },
        "bb0030": {
            "authors": [
                {
                    "first": "Volker M.",
                    "initial": "V.M.",
                    "last": "Arlt"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborova"
                },
                {
                    "first": "Alan",
                    "initial": "A.",
                    "last": "Hewer"
                },
                {
                    "first": "Heinz H.",
                    "initial": "H.H.",
                    "last": "Schmeiser"
                },
                {
                    "first": "David H.",
                    "initial": "D.H.",
                    "last": "Phillips"
                }
            ],
            "firstpage": "2752",
            "issn": "00085472",
            "lastpage": "2761",
            "pmid": "12782579",
            "pub_year": 2003,
            "title": "Human enzymes involved in the metabolic activation of the environmental contaminant 3-nitrobenzanthrone: Evidence for reductive activation by human NADPH:Cytochrome P450 reductase",
            "volume": "63"
        },
        "bb0035": {
            "authors": [
                {
                    "first": "Amrita",
                    "initial": "A.",
                    "last": "Banerjee"
                },
                {
                    "first": "Sulagna",
                    "initial": "S.",
                    "last": "Sanyal"
                },
                {
                    "first": "Parijat",
                    "initial": "P.",
                    "last": "Majumder"
                },
                {
                    "first": "Payal",
                    "initial": "P.",
                    "last": "Chakraborty"
                },
                {
                    "first": "Kuladip",
                    "initial": "K.",
                    "last": "Jana"
                },
                {
                    "first": "Chandrima",
                    "initial": "C.",
                    "last": "Das"
                },
                {
                    "first": "Dipak",
                    "initial": "D.",
                    "last": "Dasgupta"
                }
            ],
            "doi": "10.1016/j.bbrc.2015.04.140",
            "firstpage": "352",
            "issn": "0006291X",
            "lastpage": "357",
            "pmid": "25960297",
            "pub_year": 2015,
            "title": "Recognition of chromatin by the plant alkaloid, ellipticine as a dual binder",
            "volume": "462"
        },
        "bb0040": {
            "authors": [
                {
                    "first": "M. Danny",
                    "initial": "M.D.",
                    "last": "Burke"
                },
                {
                    "first": "Stephanie",
                    "initial": "S.",
                    "last": "Thompson"
                },
                {
                    "first": "Richard J.",
                    "initial": "R.J.",
                    "last": "Weaver"
                },
                {
                    "first": "C. Roland",
                    "initial": "C.R.",
                    "last": "Wolf"
                },
                {
                    "first": "Richard T.",
                    "initial": "R.T.",
                    "last": "Mayers"
                }
            ],
            "doi": "10.1016/0006-2952(94)90363-8",
            "firstpage": "923",
            "issn": "00062952",
            "lastpage": "936",
            "pmid": "8093105",
            "pub_year": 1994,
            "title": "Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver",
            "volume": "48"
        },
        "bb0045": {
            "authors": [
                {
                    "first": "Robert D.",
                    "initial": "R.D.",
                    "last": "Finn"
                },
                {
                    "first": "Lesley A.",
                    "initial": "L.A.",
                    "last": "McLaughlin"
                },
                {
                    "first": "Sebastien",
                    "initial": "S.",
                    "last": "Ronseaux"
                },
                {
                    "first": "Ian",
                    "initial": "I.",
                    "last": "Rosewell"
                },
                {
                    "first": "J. Brian",
                    "initial": "J.B.",
                    "last": "Houston"
                },
                {
                    "first": "Colin J.",
                    "initial": "C.J.",
                    "last": "Henderson"
                },
                {
                    "first": "C. Roland",
                    "initial": "C.R.",
                    "last": "Wolf"
                }
            ],
            "doi": "10.1074/jbc.M803496200",
            "firstpage": "31385",
            "issn": "00219258",
            "lastpage": "31393",
            "pmid": "18805792",
            "pub_year": 2008,
            "title": "Defining the in vivo role for cytochrome b5 in cytochrome P450 function through the conditional hepatic deletion of microsomal cytochrome b5",
            "volume": "283"
        },
        "bb0050": {
            "authors": [
                {
                    "first": "Nichola C.",
                    "initial": "N.C.",
                    "last": "Garbett"
                },
                {
                    "first": "David E.",
                    "initial": "D.E.",
                    "last": "Graves"
                }
            ],
            "doi": "10.2174/1568011043482070",
            "firstpage": "149",
            "issn": "15680118",
            "lastpage": "172",
            "pmid": "15032720",
            "pub_year": 2004,
            "title": "Extending nature's leads: The anticancer agent ellipticine",
            "volume": "4"
        },
        "bb0055": {
            "authors": [
                {
                    "first": "Colin J.",
                    "initial": "C.J.",
                    "last": "Henderson"
                },
                {
                    "first": "Lesley A.",
                    "initial": "L.A.",
                    "last": "McLaughlin"
                },
                {
                    "first": "Robert D.",
                    "initial": "R.D.",
                    "last": "Finn"
                },
                {
                    "first": "Sebastien",
                    "initial": "S.",
                    "last": "Ronseaux"
                },
                {
                    "first": "Yury",
                    "initial": "Y.",
                    "last": "Kapelyukh"
                },
                {
                    "first": "C. Roland",
                    "initial": "C.R.",
                    "last": "Wolf"
                }
            ],
            "doi": "10.1124/dmd.113.055277",
            "firstpage": "70",
            "issn": "00909556",
            "lastpage": "77",
            "pmid": "24115751",
            "pub_year": 2014,
            "title": "A role for cytochrome b5 in the in vivo disposition of anticancer and cytochrome P450 probe drugs in mice",
            "volume": "42"
        },
        "bb0060": {
            "authors": [
                {
                    "first": "Colin J.",
                    "initial": "C.J.",
                    "last": "Henderson"
                },
                {
                    "first": "Lesley A.",
                    "initial": "L.A.",
                    "last": "McLaughlin"
                },
                {
                    "first": "C. Roland",
                    "initial": "C.R.",
                    "last": "Wolf"
                }
            ],
            "doi": "10.1124/mol.112.084616",
            "firstpage": "1209",
            "issn": "0026895X",
            "lastpage": "1217",
            "pmid": "23530090",
            "pub_year": 2013,
            "title": "Evidence that cytochrome b5 and cytochrome b5 reductase can act as sole electron donors to the hepatic cytochrome p450 systems",
            "volume": "83"
        },
        "bb0065": {
            "authors": [
                {
                    "first": "Colin J.",
                    "initial": "C.J.",
                    "last": "Henderson"
                },
                {
                    "first": "Diana M.E.",
                    "initial": "D.M.E.",
                    "last": "Otto"
                },
                {
                    "first": "Dianne",
                    "initial": "D.",
                    "last": "Carrie"
                },
                {
                    "first": "Mark A.",
                    "initial": "M.A.",
                    "last": "Magnuson"
                },
                {
                    "first": "Aileen W.",
                    "initial": "A.W.",
                    "last": "McLaren"
                },
                {
                    "first": "Ian",
                    "initial": "I.",
                    "last": "Rosewell"
                },
                {
                    "first": "C. Roland",
                    "initial": "C.R.",
                    "last": "Wolf"
                }
            ],
            "doi": "10.1074/jbc.M212087200",
            "firstpage": "13480",
            "issn": "00219258",
            "lastpage": "13486",
            "pmid": "12566435",
            "pub_year": 2003,
            "title": "Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase",
            "volume": "278"
        },
        "bb0070": {
            "authors": [
                {
                    "first": "V\u011bra",
                    "initial": "V.",
                    "last": "Kotrbov\u00e1"
                },
                {
                    "first": "Dagmar",
                    "initial": "D.",
                    "last": "Aimov\u00e1"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "B\u0159ezinov\u00e1"
                },
                {
                    "first": "Kate\u0159ina",
                    "initial": "K.",
                    "last": "Janouchov\u00e1"
                },
                {
                    "first": "Jitka",
                    "initial": "J.",
                    "last": "Poljakov\u00e1"
                },
                {
                    "first": "Petr",
                    "initial": "P.",
                    "last": "Hodek"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                }
            ],
            "firstpage": "18",
            "issn": "0172780X",
            "lastpage": "20",
            "pmid": "17159771",
            "pub_year": 2006,
            "title": "Cytohromes P450 reconstituted with NADPH: P450 reductase mimic the activating and detoxicating metabolism of the anticancer drug ellipticine in microsomes",
            "volume": "27"
        },
        "bb0075": {
            "authors": [
                {
                    "first": "V\u011bra",
                    "initial": "V.",
                    "last": "Kotrbov\u00e1"
                },
                {
                    "first": "Barbora",
                    "initial": "B.",
                    "last": "Mr\u00e1zov\u00e1"
                },
                {
                    "first": "Michaela",
                    "initial": "M.",
                    "last": "Moserov\u00e1"
                },
                {
                    "first": "V\u00e1clav",
                    "initial": "V.",
                    "last": "Mart\u00ednek"
                },
                {
                    "first": "Petr",
                    "initial": "P.",
                    "last": "Hodek"
                },
                {
                    "first": "Ji\u0159\u00ed",
                    "initial": "J.",
                    "last": "Hude\u010dek"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                }
            ],
            "doi": "10.1016/j.bcp.2011.06.003",
            "firstpage": "669",
            "issn": "00062952",
            "lastpage": "680",
            "pmid": "21683692",
            "pub_year": 2011,
            "title": "Cytochrome b5 shifts oxidation of the anticancer drug ellipticine by cytochromes P450 1A1 and 1A2 from its detoxication to activation, thereby modulating its pharmacological efficacy",
            "volume": "82"
        },
        "bb0080": {
            "authors": [
                {
                    "first": "Kate\u0159ina",
                    "initial": "K.",
                    "last": "Levov\u00e1"
                },
                {
                    "first": "Michaela",
                    "initial": "M.",
                    "last": "Moserov\u00e1"
                },
                {
                    "first": "V\u011bra",
                    "initial": "V.",
                    "last": "Kotrbov\u00e1"
                },
                {
                    "first": "Miroslav",
                    "initial": "M.",
                    "last": "\u0160ulc"
                },
                {
                    "first": "Colin J.",
                    "initial": "C.J.",
                    "last": "Henderson"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Roland Wolf"
                },
                {
                    "first": "David H.",
                    "initial": "D.H.",
                    "last": "Phillips"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                },
                {
                    "first": "Heinz H.",
                    "initial": "H.H.",
                    "last": "Schmeiser"
                },
                {
                    "first": "Jaroslav",
                    "initial": "J.",
                    "last": "Mare\u0161"
                },
                {
                    "first": "Volker M.",
                    "initial": "V.M.",
                    "last": "Arlt"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                }
            ],
            "doi": "10.1093/toxsci/kfr050",
            "firstpage": "43",
            "issn": "10966080",
            "lastpage": "56",
            "pmid": "21362632",
            "pub_year": 2011,
            "title": "Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: Studies with the hepatic NADPH: Cytochrome P450 reductase null (HRN) mouse model",
            "volume": "121"
        },
        "bb0085": {
            "authors": [
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Martinkova"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Maglott"
                },
                {
                    "first": "David Y.",
                    "initial": "D.Y.",
                    "last": "Leger"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Bonnet"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborova"
                },
                {
                    "first": "Ken",
                    "initial": "K.",
                    "last": "Takeda"
                },
                {
                    "first": "Sophie",
                    "initial": "S.",
                    "last": "Martin"
                },
                {
                    "first": "Monique",
                    "initial": "M.",
                    "last": "Dontenwill"
                }
            ],
            "doi": "10.1002/ijc.25187",
            "firstpage": "1240",
            "issn": "00207136",
            "lastpage": "1248",
            "pmid": "20099278",
            "pub_year": 2010,
            "title": "\u03b15\u03b21 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells",
            "volume": "127"
        },
        "bb0090": {
            "authors": [
                {
                    "first": "Charlotte M.",
                    "initial": "C.M.",
                    "last": "Miller"
                },
                {
                    "first": "Florence O.",
                    "initial": "F.O.",
                    "last": "McCarthy"
                }
            ],
            "doi": "10.1039/c2ra20584j",
            "firstpage": "8883",
            "issn": "20462069",
            "lastpage": "8918",
            "pub_year": 2012,
            "title": "Isolation, biological activity and synthesis of the natural product ellipticine and related pyridocarbazoles",
            "volume": "2"
        },
        "bb0095": {
            "authors": [
                {
                    "first": "Daniel W.",
                    "initial": "D.W.",
                    "last": "Nebert"
                },
                {
                    "first": "Zhanquan",
                    "initial": "Z.",
                    "last": "Shi"
                },
                {
                    "first": "Marina",
                    "initial": "M.",
                    "last": "G\u00e1lvez-Peralta"
                },
                {
                    "first": "Shigeyuki",
                    "initial": "S.",
                    "last": "Uno"
                },
                {
                    "first": "Nadine",
                    "initial": "N.",
                    "last": "Dragin"
                }
            ],
            "doi": "10.1124/mol.113.086637",
            "firstpage": "304",
            "issn": "0026895X",
            "lastpage": "313",
            "pmid": "23761301",
            "pub_year": 2013,
            "title": "Oral benzo[a]pyrene: Understanding pharmacokinetics, detoxication, and consequences - Cyp1 knockout mouse lines as a paradigm",
            "volume": "84"
        },
        "bb0100": {
            "authors": [
                {
                    "first": "Jitka",
                    "initial": "J.",
                    "last": "Poljakov\u00e1"
                },
                {
                    "first": "Kristina",
                    "initial": "K.",
                    "last": "Forsterov\u00e1"
                },
                {
                    "first": "Miroslav",
                    "initial": "M.",
                    "last": "Sulc"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                }
            ],
            "doi": "10.5507/bp.2005.078",
            "firstpage": "449",
            "issn": "12138118",
            "lastpage": "453",
            "pmid": "16601808",
            "pub_year": 2005,
            "title": "Oxidation of an antitumor drug ellipticine by peroxidases.",
            "volume": "149"
        },
        "bb0105": {
            "authors": [
                {
                    "first": "Lindsay",
                    "initial": "L.",
                    "last": "Reed"
                },
                {
                    "first": "Volker M.",
                    "initial": "V.M.",
                    "last": "Arlt"
                },
                {
                    "first": "David H.",
                    "initial": "D.H.",
                    "last": "Phillips"
                }
            ],
            "doi": "10.1093/carcin/bgy058",
            "firstpage": "851",
            "issn": "01433334",
            "lastpage": "859",
            "pmid": "29726902",
            "pub_year": 2018,
            "title": "The role of cytochrome P450 enzymes in carcinogen activation and detoxication: An in vivo-in vitro paradox",
            "volume": "39"
        },
        "bb0110": {
            "authors": [
                {
                    "first": "Lindsay",
                    "initial": "L.",
                    "last": "Reed"
                },
                {
                    "first": "Iveta",
                    "initial": "I.",
                    "last": "Mrizova"
                },
                {
                    "first": "Frantisek",
                    "initial": "F.",
                    "last": "Barta"
                },
                {
                    "first": "Radek",
                    "initial": "R.",
                    "last": "Indra"
                },
                {
                    "first": "Michaela",
                    "initial": "M.",
                    "last": "Moserova"
                },
                {
                    "first": "Klaus",
                    "initial": "K.",
                    "last": "Kopka"
                },
                {
                    "first": "Heinz H.",
                    "initial": "H.H.",
                    "last": "Schmeiser"
                },
                {
                    "first": "C. Roland",
                    "initial": "C.R.",
                    "last": "Wolf"
                },
                {
                    "first": "Colin J.",
                    "initial": "C.J.",
                    "last": "Henderson"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborova"
                },
                {
                    "first": "David H.",
                    "initial": "D.H.",
                    "last": "Phillips"
                },
                {
                    "first": "Volker M.",
                    "initial": "V.M.",
                    "last": "Arlt"
                }
            ],
            "doi": "10.1007/s00204-018-2162-7",
            "firstpage": "1625",
            "issn": "03405761",
            "lastpage": "1638",
            "pmid": "29368147",
            "pub_year": 2018,
            "title": "Cytochrome b5 impacts on cytochrome P450-mediated metabolism of benzo[a]pyrene and its DNA adduct formation: studies in hepatic cytochrome b5/P450 reductase null (HBRN) mice",
            "volume": "92"
        },
        "bb0115": {
            "authors": [
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                },
                {
                    "first": "Volker M.",
                    "initial": "V.M.",
                    "last": "Arlt"
                },
                {
                    "first": "Colin J.",
                    "initial": "C.J.",
                    "last": "Henderson"
                },
                {
                    "first": "C. Roland",
                    "initial": "C.R.",
                    "last": "Wolf"
                },
                {
                    "first": "V\u011bra",
                    "initial": "V.",
                    "last": "Kotrbov\u00e1"
                },
                {
                    "first": "Michaela",
                    "initial": "M.",
                    "last": "Moserov\u00e1"
                },
                {
                    "first": "Ji\u0159\u00ed",
                    "initial": "J.",
                    "last": "Hude\u010dek"
                },
                {
                    "first": "David H.",
                    "initial": "D.H.",
                    "last": "Phillips"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                }
            ],
            "doi": "10.1016/j.taap.2007.09.017",
            "firstpage": "318",
            "issn": "0041008X",
            "lastpage": "327",
            "pmid": "17976674",
            "pub_year": 2008,
            "title": "Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: Studies with the hepatic NADPH:Cytochrome P450 reductase null mouse",
            "volume": "226"
        },
        "bb0120": {
            "authors": [
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                },
                {
                    "first": "Christian A.",
                    "initial": "C.A.",
                    "last": "Bieler"
                },
                {
                    "first": "Manfred",
                    "initial": "M.",
                    "last": "Wiessler"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                }
            ],
            "doi": "10.1016/S0006-2952(01)00806-1",
            "firstpage": "1675",
            "issn": "00062952",
            "lastpage": "1684",
            "pmid": "11755121",
            "pub_year": 2001,
            "title": "The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts",
            "volume": "62"
        },
        "bb0125": {
            "authors": [
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Bo\u0159ek-Dohalsk\u00e1"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Aimov\u00e1"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Kotrbov\u00e1"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Kuka\u010dkov\u00e1"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Janouchov\u00e1"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Rupertov\u00e1"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Ry\u0161lav\u00e1"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Hude\u010dek"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Frei"
                }
            ],
            "firstpage": "245",
            "issn": "02315882",
            "lastpage": "261",
            "pmid": "17197724",
            "pub_year": 2006,
            "title": "Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - Similarity between human and rat systems",
            "volume": "25"
        },
        "bb0130": {
            "authors": [
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                },
                {
                    "first": "Andrea",
                    "initial": "A.",
                    "last": "Breuer"
                },
                {
                    "first": "Dagmar",
                    "initial": "D.",
                    "last": "Aimov\u00e1"
                },
                {
                    "first": "Martina",
                    "initial": "M.",
                    "last": "Stibrov\u00e1-Rupertov\u00e1"
                },
                {
                    "first": "Manfred",
                    "initial": "M.",
                    "last": "Wiessler"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                }
            ],
            "doi": "10.1002/ijc.11511",
            "firstpage": "885",
            "issn": "00207136",
            "lastpage": "890",
            "pmid": "14601046",
            "pub_year": 2003,
            "title": "DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling",
            "volume": "107"
        },
        "bb0135": {
            "authors": [
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborova"
                },
                {
                    "first": "Vera",
                    "initial": "V.",
                    "last": "Cerna"
                },
                {
                    "first": "Michaela",
                    "initial": "M.",
                    "last": "Moserova"
                },
                {
                    "first": "Volker M.",
                    "initial": "V.M.",
                    "last": "Arlt"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                }
            ],
            "firstpage": "43",
            "issn": "0172780X",
            "lastpage": "54",
            "pmid": "24362092",
            "pub_year": 2013,
            "title": "The effect of benzo[a]pyrene on metabolic activation of anticancer drug ellipticine in mice",
            "volume": "34"
        },
        "bb0140": {
            "authors": [
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                },
                {
                    "first": "V\u011bra",
                    "initial": "V.",
                    "last": "\u010cern\u00e1"
                },
                {
                    "first": "Michaela",
                    "initial": "M.",
                    "last": "Moserov\u00e1"
                },
                {
                    "first": "Iveta",
                    "initial": "I.",
                    "last": "Mr\u00edzov\u00e1"
                },
                {
                    "first": "Volker M.",
                    "initial": "V.M.",
                    "last": "Arlt"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                }
            ],
            "doi": "10.3390/ijms16010284",
            "firstpage": "284",
            "issn": "16616596",
            "lastpage": "306",
            "pmid": "25547492",
            "pub_year": 2015,
            "title": "The anticancer drug ellipticine activated with cytochrome P450 mediates DNA damage determining its pharmacological efficiencies: Studies with rats, hepatic cytochrome P450 reductase null (HRN\u2122) mice and pure enzymes",
            "volume": "16"
        },
        "bb0145": {
            "authors": [
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                }
            ],
            "doi": "10.2174/09298673113206660272",
            "firstpage": "575",
            "issn": "09298673",
            "lastpage": "591",
            "pmid": "24059226",
            "pub_year": 2014,
            "title": "Ellipticines as DNA-targeted chemotherapeutics",
            "volume": "21"
        },
        "bb0150": {
            "authors": [
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                },
                {
                    "first": "Radek",
                    "initial": "R.",
                    "last": "Indra"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                },
                {
                    "first": "Kate\u0159ina",
                    "initial": "K.",
                    "last": "Kope\u010dkov\u00e1"
                },
                {
                    "first": "Heinz H.",
                    "initial": "H.H.",
                    "last": "Schmeiser"
                },
                {
                    "first": "Tom\u00e1\u0161",
                    "initial": "T.",
                    "last": "Eckschlager"
                },
                {
                    "first": "Vojt\u011bch",
                    "initial": "V.",
                    "last": "Adam"
                },
                {
                    "first": "Zbyn\u011bk",
                    "initial": "Z.",
                    "last": "Heger"
                },
                {
                    "first": "Volker M.",
                    "initial": "V.M.",
                    "last": "Arlt"
                },
                {
                    "first": "V\u00e1clav",
                    "initial": "V.",
                    "last": "Mart\u00ednek"
                }
            ],
            "doi": "10.1007/s00706-017-1986-9",
            "firstpage": "1983",
            "issn": "00269247",
            "lastpage": "1991",
            "pub_year": 2017,
            "title": "Cytochrome b 5 plays a dual role in the reaction cycle of cytochrome P450 3A4 during oxidation of the anticancer drug ellipticine",
            "volume": "148"
        },
        "bb0155": {
            "authors": [
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                },
                {
                    "first": "Radek",
                    "initial": "R.",
                    "last": "Indra"
                },
                {
                    "first": "Michaela",
                    "initial": "M.",
                    "last": "Moserov\u00e1"
                },
                {
                    "first": "V\u011bra",
                    "initial": "V.",
                    "last": "\u010cern\u00e1"
                },
                {
                    "first": "Martina",
                    "initial": "M.",
                    "last": "Rupertov\u00e1"
                },
                {
                    "first": "V\u00e1clav",
                    "initial": "V.",
                    "last": "Mart\u00ednek"
                },
                {
                    "first": "Tom\u00e1\u0161",
                    "initial": "T.",
                    "last": "Eckschlager"
                },
                {
                    "first": "Ren\u00e9",
                    "initial": "R.",
                    "last": "Kizek"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                }
            ],
            "doi": "10.1021/tx3000335",
            "firstpage": "1075",
            "issn": "0893228X",
            "lastpage": "1085",
            "pmid": "22390216",
            "pub_year": 2012,
            "title": "Cytochrome b5 increases cytochrome P450 3A4-mediated activation of anticancer drug ellipticine to 13-hydroxyellipticine whose covalent binding to DNA is elevated by sulfotransferases and N,O-acetyltransferases",
            "volume": "25"
        },
        "bb0160": {
            "authors": [
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                },
                {
                    "first": "Kater\u01d0na",
                    "initial": "K.",
                    "last": "Levov\u00e1"
                },
                {
                    "first": "Franti\u0161ek",
                    "initial": "F.",
                    "last": "B\u00e1rta"
                },
                {
                    "first": "Zhanquan",
                    "initial": "Z.",
                    "last": "Shi"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                },
                {
                    "first": "Heinz H.",
                    "initial": "H.H.",
                    "last": "Schmeiser"
                },
                {
                    "first": "Daniel W.",
                    "initial": "D.W.",
                    "last": "Nebert"
                },
                {
                    "first": "David H.",
                    "initial": "D.H.",
                    "last": "Phillips"
                },
                {
                    "first": "Volker M.",
                    "initial": "V.M.",
                    "last": "Arlt"
                }
            ],
            "doi": "10.1093/toxsci/kfr306",
            "firstpage": "345",
            "issn": "10966080",
            "lastpage": "358",
            "pmid": "22086975",
            "pub_year": 2012,
            "title": "Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid i by human cytochrome P450 1A1 and 1A2",
            "volume": "125"
        },
        "bb0165": {
            "authors": [
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborova"
                },
                {
                    "first": "Zuzana",
                    "initial": "Z.",
                    "last": "Manhartova"
                },
                {
                    "first": "Petr",
                    "initial": "P.",
                    "last": "Hodek"
                },
                {
                    "first": "Vojtech",
                    "initial": "V.",
                    "last": "Adam"
                },
                {
                    "first": "Rene",
                    "initial": "R.",
                    "last": "Kizek"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                }
            ],
            "doi": "10.3390/s141222982",
            "firstpage": "22982",
            "issn": "14248220",
            "lastpage": "22997",
            "pmid": "25479328",
            "pub_year": 2014,
            "title": "Formation of DNA Adducts by Ellipticine and its Micellar form in Rats \u2014 A Comparative Study",
            "volume": "14"
        },
        "bb0170": {
            "authors": [
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                },
                {
                    "first": "V\u00e1clav",
                    "initial": "V.",
                    "last": "Mart\u00ednek"
                },
                {
                    "first": "Helena",
                    "initial": "H.",
                    "last": "R\u00fddlov\u00e1"
                },
                {
                    "first": "Petr",
                    "initial": "P.",
                    "last": "Hodek"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                }
            ],
            "firstpage": "5678",
            "issn": "00085472",
            "lastpage": "5684",
            "pmid": "12384524",
            "pub_year": 2002,
            "title": "Sudan I is a potential carcinogen for humans: Evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes",
            "volume": "62"
        },
        "bb0175": {
            "authors": [
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                },
                {
                    "first": "V\u00e1clav",
                    "initial": "V.",
                    "last": "Mart\u00ednek"
                },
                {
                    "first": "Helena",
                    "initial": "H.",
                    "last": "R\u00fddlov\u00e1"
                },
                {
                    "first": "Tom\u00e1\u0161",
                    "initial": "T.",
                    "last": "Koblas"
                },
                {
                    "first": "Petr",
                    "initial": "P.",
                    "last": "Hodek"
                }
            ],
            "doi": "10.1016/j.canlet.2004.07.036",
            "firstpage": "145",
            "issn": "03043835",
            "lastpage": "154",
            "pmid": "15766589",
            "pub_year": 2005,
            "title": "Expression of cytochrome P450 1A1 and its contribution to oxidation of a potential human carcinogen 1-phenylazo-2-naphthol (Sudan I) in human livers",
            "volume": "220"
        },
        "bb0180": {
            "authors": [
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                },
                {
                    "first": "Michaela",
                    "initial": "M.",
                    "last": "Moserov\u00e1"
                },
                {
                    "first": "Iveta",
                    "initial": "I.",
                    "last": "Mr\u00edzov\u00e1"
                },
                {
                    "first": "Helena",
                    "initial": "H.",
                    "last": "Dra\u010d\u00ednsk\u00e1"
                },
                {
                    "first": "V\u00e1clav",
                    "initial": "V.",
                    "last": "Mart\u00ednek"
                },
                {
                    "first": "Radek",
                    "initial": "R.",
                    "last": "Indra"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                },
                {
                    "first": "Vojt\u011bch",
                    "initial": "V.",
                    "last": "Adam"
                },
                {
                    "first": "Ren\u00e9",
                    "initial": "R.",
                    "last": "Kizek"
                },
                {
                    "first": "Heinz H.",
                    "initial": "H.H.",
                    "last": "Schmeiser"
                },
                {
                    "first": "Kate\u0159ina",
                    "initial": "K.",
                    "last": "Kub\u00e1\u010dkov\u00e1"
                },
                {
                    "first": "Volker M.",
                    "initial": "V.M.",
                    "last": "Arlt"
                }
            ],
            "doi": "10.1007/s00706-015-1636-z",
            "firstpage": "897",
            "issn": "00269247",
            "lastpage": "904",
            "pub_year": 2016,
            "title": "Induced expression of microsomal cytochrome b 5 determined at mRNA and protein levels in rats exposed to ellipticine, benzo[a]pyrene, and 1-phenylazo-2-naphthol (Sudan I)",
            "volume": "147"
        },
        "bb0185": {
            "authors": [
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                },
                {
                    "first": "Jitka",
                    "initial": "J.",
                    "last": "Poljakov\u00e1"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Mart\u00ednkov\u00e1"
                },
                {
                    "first": "Jitka",
                    "initial": "J.",
                    "last": "Ulrichov\u00e1"
                },
                {
                    "first": "Vil\u00edm",
                    "initial": "V.",
                    "last": "\u0160im\u00e1nek"
                },
                {
                    "first": "Zden\u011bk",
                    "initial": "Z.",
                    "last": "Dvo\u0159\u00e1k"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                }
            ],
            "doi": "10.1016/j.tox.2012.08.004",
            "firstpage": "233",
            "issn": "0300483X",
            "lastpage": "241",
            "pmid": "22917556",
            "pub_year": 2012,
            "title": "Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5",
            "volume": "302"
        },
        "bb0190": {
            "authors": [
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                },
                {
                    "first": "Jitka",
                    "initial": "J.",
                    "last": "Poljakov\u00e1"
                },
                {
                    "first": "Helena",
                    "initial": "H.",
                    "last": "Ry\u0161lav\u00e1"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Dra\u010d\u00ednsk\u00fd"
                },
                {
                    "first": "Tom\u00e1\u0161",
                    "initial": "T.",
                    "last": "Eckschlager"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                }
            ],
            "doi": "10.1002/ijc.22247",
            "firstpage": "243",
            "issn": "00207136",
            "lastpage": "251",
            "pmid": "17066455",
            "pub_year": 2007,
            "title": "Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine",
            "volume": "120"
        },
        "bb0195": {
            "authors": [
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                },
                {
                    "first": "Martina",
                    "initial": "M.",
                    "last": "Rupertov\u00e1"
                },
                {
                    "first": "Dagmar",
                    "initial": "D.",
                    "last": "Aimov\u00e1"
                },
                {
                    "first": "Helena",
                    "initial": "H.",
                    "last": "Ry\u0161lav\u00e1"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                }
            ],
            "doi": "10.1016/j.tox.2007.03.026",
            "firstpage": "50",
            "issn": "0300483X",
            "lastpage": "60",
            "pmid": "17482743",
            "pub_year": 2007,
            "title": "Formation and persistence of DNA adducts of anticancer drug ellipticine in rats",
            "volume": "236"
        },
        "bb0200": {
            "authors": [
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Rupertov\u00e1"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Frei"
                }
            ],
            "doi": "10.1016/j.bbapap.2010.05.016",
            "firstpage": "175",
            "issn": "15709639",
            "lastpage": "185",
            "pmid": "20576524",
            "pub_year": 2011,
            "title": "Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency",
            "volume": "1814"
        },
        "bb0205": {
            "authors": [
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Sejbal"
                },
                {
                    "first": "Lucie",
                    "initial": "L.",
                    "last": "Bo\u0159ek-Dohalsk\u00e1"
                },
                {
                    "first": "Dagmar",
                    "initial": "D.",
                    "last": "Aimov\u00e1"
                },
                {
                    "first": "Jitka",
                    "initial": "J.",
                    "last": "Poljakov\u00e1"
                },
                {
                    "first": "Kristina",
                    "initial": "K.",
                    "last": "Forsterov\u00e1"
                },
                {
                    "first": "Martina",
                    "initial": "M.",
                    "last": "Rupertov\u00e1"
                },
                {
                    "first": "Ji\u0159\u00ed",
                    "initial": "J.",
                    "last": "Wiesner"
                },
                {
                    "first": "Ji\u0159\u00ed",
                    "initial": "J.",
                    "last": "Hude\u010dek"
                },
                {
                    "first": "Manfred",
                    "initial": "M.",
                    "last": "Wiessler"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                }
            ],
            "doi": "10.1158/0008-5472.CAN-04-2202",
            "firstpage": "8374",
            "issn": "00085472",
            "lastpage": "8380",
            "pmid": "15548707",
            "pub_year": 2004,
            "title": "The anticancer drug ellipticine forms covalent DNA adducts, mediated by human cytochromes P450, through metabolism to 13-hydroxyellipticine and ellipticine N2-oxide",
            "volume": "64"
        },
        "bb0210": {
            "authors": [
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborov\u00e1"
                },
                {
                    "first": "Martina",
                    "initial": "M.",
                    "last": "Stiborov\u00e1-Rupertov\u00e1"
                },
                {
                    "first": "Lucie",
                    "initial": "L.",
                    "last": "Bo\u0159ek-Dohalsk\u00e1"
                },
                {
                    "first": "Manfred",
                    "initial": "M.",
                    "last": "Wiessler"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Frei"
                }
            ],
            "doi": "10.1021/tx0200818",
            "firstpage": "38",
            "issn": "0893228X",
            "lastpage": "47",
            "pmid": "12693029",
            "pub_year": 2003,
            "title": "Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans",
            "volume": "16"
        },
        "bb0215": {
            "authors": [
                {
                    "first": "Kendra R.",
                    "initial": "K.R.",
                    "last": "Vann"
                },
                {
                    "first": "Yavuz",
                    "initial": "Y.",
                    "last": "Erg\u00fcn"
                },
                {
                    "first": "Sevil",
                    "initial": "S.",
                    "last": "Zencir"
                },
                {
                    "first": "Serkan",
                    "initial": "S.",
                    "last": "Oncuoglu"
                },
                {
                    "first": "Neil",
                    "initial": "N.",
                    "last": "Osheroff"
                },
                {
                    "first": "Zeki",
                    "initial": "Z.",
                    "last": "Topcu"
                }
            ],
            "doi": "10.1016/j.bmcl.2016.02.034",
            "firstpage": "1809",
            "issn": "0960894X",
            "lastpage": "1812",
            "pmid": "26906637",
            "pub_year": 2016,
            "title": "Inhibition of human DNA topoisomerase II\u03b1 by two novel ellipticine derivatives",
            "volume": "26"
        },
        "bb0220": {
            "authors": [
                {
                    "first": "Alexandra J.",
                    "initial": "A.J.",
                    "last": "Willis"
                },
                {
                    "first": "Radek",
                    "initial": "R.",
                    "last": "Indra"
                },
                {
                    "first": "Laura E.",
                    "initial": "L.E.",
                    "last": "Wohak"
                },
                {
                    "first": "Osman",
                    "initial": "O.",
                    "last": "Sozeri"
                },
                {
                    "first": "Kerstin",
                    "initial": "K.",
                    "last": "Feser"
                },
                {
                    "first": "Iveta",
                    "initial": "I.",
                    "last": "Mrizova"
                },
                {
                    "first": "David H.",
                    "initial": "D.H.",
                    "last": "Phillips"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Stiborova"
                },
                {
                    "first": "Volker M.",
                    "initial": "V.M.",
                    "last": "Arlt"
                }
            ],
            "doi": "10.1016/j.tox.2018.02.006",
            "firstpage": "1",
            "issn": "0300483X",
            "lastpage": "12",
            "pmid": "29471073",
            "pub_year": 2018,
            "title": "The impact of chemotherapeutic drugs on the CYP1A1-catalysed metabolism of the environmental carcinogen benzo[a]pyrene: Effects in human colorectal HCT116 TP53(+/+), TP53(+/\u2212) and TP53(\u2212/\u2212) cells",
            "volume": "398-399"
        },
        "bb0225": {
            "authors": [
                {
                    "first": "Hiroshi",
                    "initial": "H.",
                    "last": "Yamazaki"
                },
                {
                    "first": "Mami",
                    "initial": "M.",
                    "last": "Nakamura"
                },
                {
                    "first": "Tomoko",
                    "initial": "T.",
                    "last": "Komatsu"
                },
                {
                    "first": "Katsuhiro",
                    "initial": "K.",
                    "last": "Ohyama"
                },
                {
                    "first": "Naoya",
                    "initial": "N.",
                    "last": "Hatanaka"
                },
                {
                    "first": "Satoru",
                    "initial": "S.",
                    "last": "Asahi"
                },
                {
                    "first": "Noriaki",
                    "initial": "N.",
                    "last": "Shimada"
                },
                {
                    "first": "F. Peter",
                    "initial": "F.P.",
                    "last": "Guengerich"
                },
                {
                    "first": "Tsutomu",
                    "initial": "T.",
                    "last": "Shimada"
                },
                {
                    "first": "Miki",
                    "initial": "M.",
                    "last": "Nakajima"
                },
                {
                    "first": "Tsuyoshi",
                    "initial": "T.",
                    "last": "Yokoi"
                }
            ],
            "doi": "10.1006/prep.2001.1578",
            "firstpage": "329",
            "issn": "10465928",
            "lastpage": "337",
            "pmid": "11922748",
            "pub_year": 2002,
            "title": "Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli",
            "volume": "24"
        },
        "bb0230": {
            "authors": [
                {
                    "first": "Hiroshi",
                    "initial": "H.",
                    "last": "Yamazaki"
                },
                {
                    "first": "Masami",
                    "initial": "M.",
                    "last": "Nakano"
                },
                {
                    "first": "Elizabeth M.J.",
                    "initial": "E.M.J.",
                    "last": "Gillam"
                },
                {
                    "first": "L. Chastine",
                    "initial": "L.C.",
                    "last": "Bell"
                },
                {
                    "first": "F. Peter",
                    "initial": "F.P.",
                    "last": "Guengerich"
                },
                {
                    "first": "Tsutomu",
                    "initial": "T.",
                    "last": "Shimada"
                }
            ],
            "doi": "10.1016/0006-2952(96)00208-0",
            "firstpage": "301",
            "issn": "00062952",
            "lastpage": "309",
            "pmid": "8694855",
            "pub_year": 1996,
            "title": "Requirements for cytochrome b5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline, and N-nitrosodimethylamine by recombinant cytochrome P450 2E1 and by human liver microsomes",
            "volume": "52"
        },
        "bb0235": {
            "authors": [
                {
                    "first": "Hiroshi",
                    "initial": "H.",
                    "last": "Yamazaki"
                },
                {
                    "first": "Masami",
                    "initial": "M.",
                    "last": "Nakano"
                },
                {
                    "first": "Yoshio",
                    "initial": "Y.",
                    "last": "Imai"
                },
                {
                    "first": "Yune Fang",
                    "initial": "Y.F.",
                    "last": "Ueng"
                },
                {
                    "first": "F. Peter",
                    "initial": "F.P.",
                    "last": "Guengerich"
                },
                {
                    "first": "Tsutomu",
                    "initial": "T.",
                    "last": "Shimada"
                }
            ],
            "doi": "10.1006/abbi.1996.0022",
            "firstpage": "174",
            "issn": "00039861",
            "lastpage": "182",
            "pmid": "8561495",
            "pub_year": 1996,
            "title": "Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes",
            "volume": "325"
        },
        "bb0240": {
            "authors": [
                {
                    "first": "Haoming",
                    "initial": "H.",
                    "last": "Zhang"
                },
                {
                    "first": "Sang Choul",
                    "initial": "S.C.",
                    "last": "Im"
                },
                {
                    "first": "Lucy",
                    "initial": "L.",
                    "last": "Waskell"
                }
            ],
            "doi": "10.1074/jbc.M703845200",
            "firstpage": "29766",
            "issn": "00219258",
            "lastpage": "29776",
            "pmid": "17693640",
            "pub_year": 2007,
            "title": "Cytochrome b5 increases the rate of product formation by cytochrome P450 2B4 and competes with cytochrome P450 reductase for a binding site on cytochrome P450 2B4",
            "volume": "282"
        }
    },
    "body_text": [
        {
            "endOffset": 23253,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Ellipticine, NADH (as disodium salt; purity ~95%), NADPH (as tetrasodium salt; ~98% purity), Sudan I and 7-methoxyresorufin were obtained from Sigma Chemical Co (St Louis, MO, USA).",
            "startOffset": 23072,
            "title": "Chemicals"
        },
        {
            "endOffset": 45410,
            "parents": [],
            "refoffsets": {
                "bb0190": {
                    "endOffset": 45408,
                    "startOffset": 45386
                }
            },
            "secId": "s0085",
            "sentence": "Numerous peroxidases such as bovine LPO, human MPO, ovine COX-2 and plant HRP have previously been shown to activate ellipticine to reactive metabolites, which form two DNA adducts analogous to those generated by the P450-mediated reactions (Stiborova et al., 2007).",
            "startOffset": 45144,
            "title": "Discussion"
        },
        {
            "endOffset": 45636,
            "parents": [],
            "refoffsets": {
                "bb0190": {
                    "endOffset": 45518,
                    "startOffset": 45496
                }
            },
            "secId": "s0085",
            "sentence": "Of the ellipticine metabolites, peroxidases predominantly form an ellipticine dimer (Stiborova et al., 2007), and generate the reactive intermediate ellipticine-13-ylium that is responsible for formation of adduct 1 (Fig. 1).",
            "startOffset": 45411,
            "title": "Discussion"
        },
        {
            "endOffset": 47727,
            "parents": [],
            "secId": "s0085",
            "sentence": "The in vivo role of Cyb5 in the activation of ellipticine in both HRN and HBRN mice appears to be less important.",
            "startOffset": 47614,
            "title": "Discussion"
        },
        {
            "endOffset": 25113,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Solvents used were: D1, 1.0 M sodium phosphate, pH 6.0; D3, 3.5 M lithium formate, 8.5 M urea, pH 4.0; D4, 0.8 M LiCl, 0.5 M Tris, 8.5 M urea, pH 9.0.",
            "startOffset": 24963,
            "title": "Ellipticine-DNA adduct detection by 32P-postlabelling analysis"
        },
        {
            "endOffset": 29507,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0050",
            "sentence": "Statistical analyses were performed with Prism GraphPad Software (Version 7.04) and P < .05 was considered significant.",
            "startOffset": 29388,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 45916,
            "parents": [],
            "refoffsets": {
                "bb0100": {
                    "endOffset": 45914,
                    "startOffset": 45892
                }
            },
            "secId": "s0085",
            "sentence": "Another metabolite detected was the N2-oxide (Fig. 1), interestingly one that is also generated by the oxidation of ellipticine by P450s and forms adduct 2 in vitro after the N2-oxide undergoes the Polonowski re-arrangement to form 12-hydroxyellipticine (Poljakova et al., 2005).",
            "startOffset": 45637,
            "title": "Discussion"
        },
        {
            "endOffset": 36979,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "DNA adduct formation in the livers of HRN and HBRN mice was significantly lower, by 62% and 73%, respectively, than in WT mice.",
            "startOffset": 36852,
            "title": "Ellipticine-DNA adduct formation in vivo"
        },
        {
            "endOffset": 26358,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bb0030": {
                    "endOffset": 26356,
                    "startOffset": 26339
                }
            },
            "secId": "s0035",
            "sentence": "POR enzyme activity was determined as described previously (Arlt et al., 2003).",
            "startOffset": 26279,
            "title": "Enzyme activity assays and immunoblotting"
        },
        {
            "endOffset": 28474,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Incubation mixtures contained 100 mM potassium phosphate buffer (pH 7.4), NADPH or NADH (1 mM), 25 \u03bcM ellipticine dissolved in 5 \u03bcl DMSO and pooled hepatic microsomal fraction (0.5 mg/ml protein) in a final volume of 500 \u03bcl.",
            "startOffset": 28250,
            "title": "Microsomal incubations for studying ellipticine metabolism"
        },
        {
            "endOffset": 31377,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Cyp1a1/2 activity in hepatic microsomes from HBRN mice was significantly lower compared to WT and HRN mice and showed the lowest level of Cyp1a1/2 activity when NADPH was present.",
            "startOffset": 31198,
            "title": "Enzyme activity of XMEs"
        },
        {
            "endOffset": 40148,
            "parents": [],
            "secId": "s0085",
            "sentence": "Total ellipticine-DNA adduct formation in vitro in the presence of NADH was lower than when NADPH was present, but not significantly different between the mouse lines.",
            "startOffset": 39981,
            "title": "Discussion"
        },
        {
            "endOffset": 31890,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Using MROD as a measure for Cyp1a2 activity, enzyme activity was similar in WT and HBRN mice (Fig. 3C).",
            "startOffset": 31787,
            "title": "Enzyme activity of XMEs"
        },
        {
            "endOffset": 37928,
            "parents": [],
            "secId": "s0085",
            "sentence": "Whilst studies with hepatic microsomal fractions demonstrated the importance of Cyb5 in the metabolic activation of BaP in vitro, DNA adduct formation in vivo showed that the absence of the electron donor POR led to greatly increased levels of DNA adducts.",
            "startOffset": 37672,
            "title": "Discussion"
        },
        {
            "endOffset": 25407,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "DNA adduct levels were calculated from the adduct cpm, the specific activity of [\u03b3-32P]ATP and the amount of DNA (pmol of DNA-P) used and results were expressed as DNA adducts/108 nucleotides.",
            "startOffset": 25215,
            "title": "Ellipticine-DNA adduct detection by 32P-postlabelling analysis"
        },
        {
            "endOffset": 22119,
            "parents": [],
            "refoffsets": {
                "bb0185": {
                    "endOffset": 22117,
                    "startOffset": 22095
                }
            },
            "secId": "s0005",
            "sentence": "These findings were supported by studies using human recombinant P450s in Supersomes\u2122 with CYP3A4 and 1A1 being the most efficient at forming ellipticine-DNA adduct 1 and with adduct 2 being formed by CYP2C19, 2C9 and 2D6 in the presence of Cyb5 (Stiborova et al., 2012).",
            "startOffset": 21848,
            "title": "Introduction"
        },
        {
            "endOffset": 42160,
            "parents": [],
            "secId": "s0085",
            "sentence": "The hepatic microsomal fractions from the present study, however, found no significant difference between DNA adduct formation in HRN or HBRN hepatic microsomal fractions regardless of the enzymatic cofactor used.",
            "startOffset": 41947,
            "title": "Discussion"
        },
        {
            "endOffset": 24579,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Animals were killed 24 h after the single dose and their tissues (liver, lung, small intestine, kidney, spleen, bladder and colon) were collected, snap-frozen and stored at \u221280 \u00b0C until analysis.",
            "startOffset": 24384,
            "title": "Animal treatment"
        },
        {
            "endOffset": 33051,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "The total formation of metabolites was highest in the hepatic microsomal fraction from WT mice when NADPH was used in the reaction mix (Fig. 5A).",
            "startOffset": 32906,
            "title": "HPLC analysis of ellipticine metabolites"
        },
        {
            "endOffset": 18892,
            "parents": [],
            "refoffsets": {
                "bb0070": {
                    "endOffset": 18890,
                    "startOffset": 18869
                },
                "bb0205": {
                    "endOffset": 18867,
                    "startOffset": 18845
                }
            },
            "secId": "s0005",
            "sentence": "The N2-oxide is also considered an active ellipticine metabolite as it converts to 12-hydroxy-ellipticine by the Polonowski rearrangement (Stiborova et al., 2004; Kotrbova et al., 2006).",
            "startOffset": 18706,
            "title": "Introduction"
        },
        {
            "endOffset": 42465,
            "parents": [],
            "secId": "s0085",
            "sentence": "Both HRN and HBRN mice showed significantly lower (~60\u201370%) hepatic ellipticine-DNA adduct formation than WT mice, but there was no significant difference between the two knockout lines.",
            "startOffset": 42279,
            "title": "Discussion"
        },
        {
            "endOffset": 22358,
            "parents": [],
            "refoffsets": {
                "bb0180": {
                    "endOffset": 22356,
                    "startOffset": 22334
                }
            },
            "secId": "s0005",
            "sentence": "Rats exposed to ellipticine have also shown a significant increase in the expression of both Cyb5 mRNA and protein, and hepatic microsomes isolated from these rats catalysed ellipticine oxidation more efficiently (Stiborova et al., 2016).",
            "startOffset": 22120,
            "title": "Introduction"
        },
        {
            "endOffset": 28734,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "After incubation, 5 \u03bcl of 1 mM phenacetin (PA) in methanol was added as an internal standard.",
            "startOffset": 28641,
            "title": "Microsomal incubations for studying ellipticine metabolism"
        },
        {
            "endOffset": 35357,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Because the adduct spots were incompletely separated total ellipticine-DNA adduct levels were determined.",
            "startOffset": 35252,
            "title": "Ellipticine-DNA adduct formation in vitro"
        },
        {
            "endOffset": 39445,
            "parents": [],
            "secId": "s0085",
            "sentence": "Cyp1a activity did not correlate with total ellipticine metabolite formation as there was no significant difference between the WT and HRN fractions with only HBRN fractions showing significant reductions compared to both WT and HRN.",
            "startOffset": 39212,
            "title": "Discussion"
        },
        {
            "endOffset": 35583,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "There was significantly less DNA adduct formation with the microsomal fractions from HRN and HBRN mice (Fig. 6A).",
            "startOffset": 35470,
            "title": "Ellipticine-DNA adduct formation in vitro"
        },
        {
            "endOffset": 38311,
            "parents": [],
            "secId": "s0085",
            "sentence": "The same approach has been utilised in this study to determine the contribution of Cyb5 to the underlying mechanism of the P450-mediated metabolic activation of ellipticine.",
            "startOffset": 38138,
            "title": "Discussion"
        },
        {
            "endOffset": 25542,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bb0110": {
                    "endOffset": 25540,
                    "startOffset": 25523
                }
            },
            "secId": "s0030",
            "sentence": "Hepatic microsomes from ellipticine-treated mice were isolated as described previously (Reed et al., 2018).",
            "startOffset": 25435,
            "title": "Preparation of microsomes"
        },
        {
            "endOffset": 33723,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "The lowest level of overall ellipticine metabolite formation was with the hepatic microsomal fractions from HBRN mice (Fig. 5A).",
            "startOffset": 33595,
            "title": "HPLC analysis of ellipticine metabolites"
        },
        {
            "endOffset": 40516,
            "parents": [],
            "refoffsets": {
                "bb0075": {
                    "endOffset": 40514,
                    "startOffset": 40493
                }
            },
            "secId": "s0085",
            "sentence": "Previous studies with reconstituted CYP1A1 and CYP1A2 showed that the presence of Cyb5 in the reaction mixture alters the resulting ellipticine metabolites profiles, with a shift from detoxication metabolites, 9-hydroxy- and/or 7-hydroxyellipticine, to metabolites that can ultimately form DNA adducts, 12-hydroxy- and/or 13-hydroxyellipticine (Kotrbova et al., 2011).",
            "startOffset": 40148,
            "title": "Discussion"
        },
        {
            "endOffset": 18342,
            "parents": [],
            "refoffsets": {
                "bb0115": {
                    "endOffset": 18292,
                    "startOffset": 18270
                },
                "bb0120": {
                    "endOffset": 18172,
                    "startOffset": 18150
                },
                "bb0130": {
                    "endOffset": 18196,
                    "startOffset": 18174
                },
                "bb0155": {
                    "endOffset": 18316,
                    "startOffset": 18294
                },
                "bb0185": {
                    "endOffset": 18340,
                    "startOffset": 18318
                },
                "bb0190": {
                    "endOffset": 18244,
                    "startOffset": 18222
                },
                "bb0195": {
                    "endOffset": 18268,
                    "startOffset": 18246
                },
                "bb0210": {
                    "endOffset": 18220,
                    "startOffset": 18198
                }
            },
            "secId": "s0005",
            "sentence": "Activation of ellipticine (i.e. generation of pharmacologically active metabolites) is catalysed by cytochrome P450 (CYP) enzymes and peroxidases, which generate reactive intermediates capable of damaging DNA by forming covalent adducts (Stiborova et al., 2001; Stiborova et al., 2003; Stiborova et al., 2003; Stiborova et al., 2007; Stiborova et al., 2007; Stiborova et al., 2008; Stiborova et al., 2012; Stiborova et al., 2012).",
            "startOffset": 17912,
            "title": "Introduction"
        },
        {
            "endOffset": 21657,
            "parents": [],
            "refoffsets": {
                "bb0075": {
                    "endOffset": 21583,
                    "startOffset": 21562
                },
                "bb0150": {
                    "endOffset": 21655,
                    "startOffset": 21633
                },
                "bb0155": {
                    "endOffset": 21607,
                    "startOffset": 21585
                },
                "bb0185": {
                    "endOffset": 21631,
                    "startOffset": 21609
                }
            },
            "secId": "s0005",
            "sentence": "Previous studies using reconstituted systems investigated the role of Cyb5 in the metabolic activation of ellipticine in vitro showed that the presence of Cyb5 resulted in a considerable increase in the activation metabolites 12-hydroxy- and 13-hydroxyellipticine (Kotrbova et al., 2011; Stiborova et al., 2012; Stiborova et al., 2012; Stiborova et al., 2017).",
            "startOffset": 21297,
            "title": "Introduction"
        },
        {
            "endOffset": 43097,
            "parents": [],
            "secId": "s0085",
            "sentence": "In vitro experiments carried out in the present study with the cofactor NADH showing Cyb5R-dependent pathways contributing to ellipticine bioactivation in HRN mice correlated with in vivo adduct formation in the lungs and small intestine of HRN mice, suggesting that the Cyb5/Cyb5R systems contributes to ellipticine-DNA adduct formation in these extrahepatic organs of HRN mice.",
            "startOffset": 42718,
            "title": "Discussion"
        },
        {
            "endOffset": 21297,
            "parents": [],
            "secId": "s0005",
            "sentence": "Cyb5 is both substrate and enzyme specific, and has been shown to both stimulate and inhibit P450 reactions, making it difficult to predict the contribution of Cyb5 to xenobiotic metabolism.",
            "startOffset": 21107,
            "title": "Introduction"
        },
        {
            "endOffset": 29922,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "bb0060": {
                    "endOffset": 29901,
                    "startOffset": 29879
                },
                "bb0110": {
                    "endOffset": 29920,
                    "startOffset": 29903
                }
            },
            "secId": "s0060",
            "sentence": "POR was expressed in the WT mice only and Cyb5 was expressed only in WT and HRN mice, as expected (Henderson et al., 2013; Reed et al., 2018).",
            "startOffset": 29780,
            "title": "Protein expression of XMEs"
        },
        {
            "endOffset": 47002,
            "parents": [],
            "secId": "s0085",
            "sentence": "Microsomal incubations with ellipticine, DNA and arachidonic acid, a cofactor for COX-dependent oxidation, showed DNA adduct formation at a level similar to that when POR, Cyp1a or Cyp3a enzymes were inhibited in hepatic microsomal fractions from untreated mice.",
            "startOffset": 46740,
            "title": "Discussion"
        },
        {
            "endOffset": 24239,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bb0115": {
                    "endOffset": 24237,
                    "startOffset": 24215
                }
            },
            "secId": "s0020",
            "sentence": "Groups of female HRN, HBRN and WT mice (3 months old, 25\u201330 g) were treated intraperitoneally (i.p.) with 10 mg/kg body wt ellipticine (n = 4/group) based on a treatment regimen used previously in HRN mice (Stiborova et al., 2008).",
            "startOffset": 24008,
            "title": "Animal treatment"
        },
        {
            "endOffset": 25816,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Pooled microsomal fractions were used for further experiments.",
            "startOffset": 25754,
            "title": "Preparation of microsomes"
        },
        {
            "endOffset": 29365,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bb0070": {
                    "endOffset": 29339,
                    "startOffset": 29318
                },
                "bb0125": {
                    "endOffset": 29363,
                    "startOffset": 29341
                },
                "bb0205": {
                    "endOffset": 29316,
                    "startOffset": 29294
                }
            },
            "secId": "s0045",
            "sentence": "Three ellipticine metabolites with the retention times of 5.7, 6.3 and 6.7 min were separated (Stiborova et al., 2004; Kotrbova et al., 2006; Stiborova et al., 2006).",
            "startOffset": 29199,
            "title": "Microsomal incubations for studying ellipticine metabolism"
        },
        {
            "endOffset": 37290,
            "parents": [],
            "secId": "s0085",
            "sentence": "Although the role of the electron donor protein Cyb5 in the metabolic activation of ellipticine has been well characterised in vitro, its role in vivo is less understood.",
            "startOffset": 37120,
            "title": "Discussion"
        },
        {
            "endOffset": 30984,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "When the cofactor for POR, NADPH, was used in the reaction mixture, hepatic microsomes from WT mice exhibited the highest levels of Cyp1a activity, except for in EROD where the levels of activity were equal in WT and HRN hepatic microsomal fractions (compare Fig. 3C-E).",
            "startOffset": 30714,
            "title": "Enzyme activity of XMEs"
        },
        {
            "endOffset": 17006,
            "parents": [],
            "secId": "s0005",
            "sentence": "Ellipticine (5,11-dimethyl-6H-pyrido[4,5-b]carbazole) is a cytotoxic alkaloid isolated from the Apocynaceae family of plants.",
            "startOffset": 16881,
            "title": "Introduction"
        },
        {
            "endOffset": 43456,
            "parents": [],
            "refoffsets": {
                "bb0115": {
                    "endOffset": 43454,
                    "startOffset": 43432
                }
            },
            "secId": "s0085",
            "sentence": "Ellipticine-DNA adduct formation in the extrahepatic organs of WT and HRN mice has been observed previously with HRN mice showing higher levels than WT mice, suggesting that ellipticine or its metabolites are being distributed via the bloodstream to organs and tissues with the metabolic capacity to oxidatively activate ellipticine (Stiborova et al., 2008).",
            "startOffset": 43098,
            "title": "Discussion"
        },
        {
            "endOffset": 37109,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "In the lung and small intestine, the levels of ellipticine-DNA adducts were significantly higher in HRN mice compared to WT mice.",
            "startOffset": 36980,
            "title": "Ellipticine-DNA adduct formation in vivo"
        },
        {
            "endOffset": 33202,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Total ellipticine metabolite formation in hepatic microsomal fractions from WT mice was around 3-fold higher compared to when NADH was used (Fig. 5B).",
            "startOffset": 33052,
            "title": "HPLC analysis of ellipticine metabolites"
        },
        {
            "endOffset": 25214,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "After chromatography TLC plates were scanned using a Packard Instant Imager (Dowers Grove, IL, USA).",
            "startOffset": 25114,
            "title": "Ellipticine-DNA adduct detection by 32P-postlabelling analysis"
        },
        {
            "endOffset": 25609,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Microsomes were isolated from 4 pooled livers of each mouse model.",
            "startOffset": 25543,
            "title": "Preparation of microsomes"
        },
        {
            "endOffset": 28100,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "After incubation, DNA was isolated by a standard phenol-chloroform extraction method.",
            "startOffset": 28015,
            "title": "Microsomal incubations for ellipticine-DNA adduct formation"
        },
        {
            "endOffset": 17911,
            "parents": [],
            "secId": "s0005",
            "sentence": "These enzyme-catalysed reactions also generate detoxication products leading to the excretion of the drug.",
            "startOffset": 17805,
            "title": "Introduction"
        },
        {
            "endOffset": 33594,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "When using NADPH as cofactor the overall formation of metabolites was significantly lower in hepatic microsomal fractions from HRN mice with production of 9-hydroxyellipticine and 13-hydroxyellipticine being significantly lower compared to WT, and 12-hydroxyellipticine not being detected (Fig. 5A).",
            "startOffset": 33295,
            "title": "HPLC analysis of ellipticine metabolites"
        },
        {
            "endOffset": 34748,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "The rate of ellipticine metabolism in the hepatic microsomal fractions correlated with the levels of Cyp1a/3a enzymatic activity and the particular enzymatic cofactor used (compare Figs. 3 and 5).",
            "startOffset": 34552,
            "title": "HPLC analysis of ellipticine metabolites"
        },
        {
            "endOffset": 45017,
            "parents": [],
            "secId": "s0085",
            "sentence": "Further investigation of this would require isolation and culture of hepatocytes and non-parenchymal liver cells from HBRN mice and exposure of these cells to ellipticine for subsequent ellipticine-DNA adduct analysis which was beyond the scope of the present study.",
            "startOffset": 44751,
            "title": "Discussion"
        },
        {
            "endOffset": 27045,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The antibody to detect glyceraldehyde phosphate dehydrogenase (Gapdh) 1:25000 (MAB374, Chemicon) was used as loading control.",
            "startOffset": 26920,
            "title": "Enzyme activity assays and immunoblotting"
        },
        {
            "endOffset": 17405,
            "parents": [],
            "refoffsets": {
                "bb0085": {
                    "endOffset": 17326,
                    "startOffset": 17303
                },
                "bb0090": {
                    "endOffset": 17377,
                    "startOffset": 17352
                },
                "bb0145": {
                    "endOffset": 17403,
                    "startOffset": 17379
                },
                "bb0200": {
                    "endOffset": 17350,
                    "startOffset": 17328
                }
            },
            "secId": "s0005",
            "sentence": "Both ellipticine and its derivatives possess anti-HIV and anti-tumour properties allowing it to be used against several cancers with limited toxic side effects and no haematological toxicity by functioning through multiple mechanisms that result in cell cycle arrest and initiation of apoptosis (Martinkova et al., 2010; Stiborova et al., 2011; Miller and McCarthy, 2012; Stiborova and Frei, 2014).",
            "startOffset": 17007,
            "title": "Introduction"
        },
        {
            "endOffset": 23579,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "All animal experiments were carried out at the University of Dundee under licence in accordance with the Animal (Scientific Procedures) Act (1986), as amended by EU Directive 2010/63/EU, and with local ethical approval.",
            "startOffset": 23360,
            "title": "Animal treatment"
        },
        {
            "endOffset": 29198,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The eluent was 64% methanol plus 36% of 5 mM heptane sulfonic acid in 32 mM acetic acid in water with a flow rate of 0.8 ml/min and detection was at 296 nm.",
            "startOffset": 29042,
            "title": "Microsomal incubations for studying ellipticine metabolism"
        },
        {
            "endOffset": 31569,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "When NADPH was used in the reaction mixture, hepatic microsomes from WT mice exhibited the highest level of Cyp3a activity, with levels being greatly lower than in the HRN and HBRN fractions.",
            "startOffset": 31378,
            "title": "Enzyme activity of XMEs"
        },
        {
            "endOffset": 38409,
            "parents": [],
            "secId": "s0085",
            "sentence": "The in vitro experiments in this study were carried out using pooled hepatic microsomal fractions.",
            "startOffset": 38311,
            "title": "Discussion"
        },
        {
            "endOffset": 26919,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "After migration the proteins were transferred onto polyvinylidene difluoride (PVDF) membranes and the following primary antibodies were used: anti-Cyp1a1 1:1000 (sc-20,772 (H-70), Santa Cruz Biotech); anti-Cyp3a 1:20000 (ab3572, Abcam); anti-Por 1:1000 (ab39995, Abcam), anti-Cyb5 1:750 (ab69801, Abcam); and anti-Cyb5R 1:1000 (ABIN453978, antibodies-online.com).",
            "startOffset": 26556,
            "title": "Enzyme activity assays and immunoblotting"
        },
        {
            "endOffset": 27877,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bb0005": {
                    "endOffset": 27875,
                    "startOffset": 27856
                }
            },
            "secId": "s0040",
            "sentence": "Incubations were carried out at 37 \u00b0C for 90 min (Aimova et al., 2008).",
            "startOffset": 27806,
            "title": "Microsomal incubations for ellipticine-DNA adduct formation"
        },
        {
            "endOffset": 28014,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Control incubations were carried out (i) without microsomes; (ii) without NADPH or NADH; (iii) without DNA and (iv) without ellipticine.",
            "startOffset": 27878,
            "title": "Microsomal incubations for ellipticine-DNA adduct formation"
        },
        {
            "endOffset": 39211,
            "parents": [],
            "secId": "s0085",
            "sentence": "In the microsomal fractions from HBRN mice the activity was significantly lower relative to WT mice, indicating that increased NADH-dependent activity is caused by the increased expression of Cyb5.",
            "startOffset": 39014,
            "title": "Discussion"
        },
        {
            "endOffset": 20253,
            "parents": [],
            "refoffsets": {
                "bb0020": {
                    "endOffset": 20251,
                    "startOffset": 20234
                },
                "bb0025": {
                    "endOffset": 20187,
                    "startOffset": 20170
                },
                "bb0080": {
                    "endOffset": 20232,
                    "startOffset": 20213
                },
                "bb0115": {
                    "endOffset": 20211,
                    "startOffset": 20189
                }
            },
            "secId": "s0005",
            "sentence": "This deletion results in the loss of essentially all hepatic P450 activity and the mice have been used to investigate hepatic versus extra-hepatic P450 mediated metabolism of several carcinogens including ellipticine (Arlt et al., 2005; Stiborova et al., 2008; Levova et al., 2011; Arlt et al., 2012).",
            "startOffset": 19952,
            "title": "Introduction"
        },
        {
            "endOffset": 38137,
            "parents": [],
            "secId": "s0085",
            "sentence": "However, the levels of BaP-DNA adducts in HBRN mice that lacked both hepatic POR and Cyb5 were significantly lower than in HRN mice demonstrating a role of Cyb5 in the metabolic activation of BaP in HRN mice.",
            "startOffset": 37929,
            "title": "Discussion"
        },
        {
            "endOffset": 39013,
            "parents": [],
            "secId": "s0085",
            "sentence": "When the NADH-dependent Cyb5R pathway was investigated, there was higher Cyp1a enzyme activity in the microsomal fractions of HRN mice than in those of WT mice.",
            "startOffset": 38853,
            "title": "Discussion"
        },
        {
            "endOffset": 26278,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bb0040": {
                    "endOffset": 26083,
                    "startOffset": 26065
                },
                "bb0150": {
                    "endOffset": 26276,
                    "startOffset": 26253
                },
                "bb0170": {
                    "endOffset": 25986,
                    "startOffset": 25964
                },
                "bb0175": {
                    "endOffset": 26184,
                    "startOffset": 26162
                }
            },
            "secId": "s0035",
            "sentence": "The hepatic microsomal fractions were characterised for Cyp1a1 enzyme activity using Sudan I oxidation (Stiborova et al., 2002), for Cyp1a2 enzyme activity using 7-methoxyresorufin O-demethylation (MROD) (Burke et al., 1994), for Cyp1a1/2 enzyme activity using 7-ethoxyresorufin O-deethylation (EROD) (Stiborova et al., 2005) and for Cyp3a enzyme activity using testosterone 6\u03b2-hydroxylation (Stiborova, et al., 2017).",
            "startOffset": 25860,
            "title": "Enzyme activity assays and immunoblotting"
        },
        {
            "endOffset": 24007,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Mice homozygous for the floxed Por locus (Porlox/lox) were used as wild-type (WT).",
            "startOffset": 23925,
            "title": "Animal treatment"
        },
        {
            "endOffset": 27461,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Incubation mixtures consisted of 100 mM potassium phosphate buffer (pH 7.4).",
            "startOffset": 27385,
            "title": "Microsomal incubations for ellipticine-DNA adduct formation"
        },
        {
            "endOffset": 32496,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Hepatic microsomes isolated from WT, HRN and HBRN mice were incubated with ellipticine and subsequently analysed by HPLC to determine the ellipticine metabolite profile.",
            "startOffset": 32327,
            "title": "HPLC analysis of ellipticine metabolites"
        },
        {
            "endOffset": 34942,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "We investigated the ability of hepatic microsomes isolated from WT, HRN and HBRN mice to catalyse ellipticine-DNA adduct formation in vitro (Fig. 6A).",
            "startOffset": 34792,
            "title": "Ellipticine-DNA adduct formation in vitro"
        },
        {
            "endOffset": 17731,
            "parents": [],
            "refoffsets": {
                "bb0035": {
                    "endOffset": 17710,
                    "startOffset": 17689
                },
                "bb0050": {
                    "endOffset": 17661,
                    "startOffset": 17637
                },
                "bb0145": {
                    "endOffset": 17687,
                    "startOffset": 17663
                },
                "bb0215": {
                    "endOffset": 17729,
                    "startOffset": 17712
                }
            },
            "secId": "s0005",
            "sentence": "The main mechanisms by which ellipticine exerts its anti-tumour, cytotoxic and mutagenic effects are inhibition of topoisomerase II, intercalation into DNA and enzyme-mediated formation of covalent ellipticine-derived DNA adducts (Garbett and Graves, 2004; Stiborova and Frei, 2014; Banerjee et al., 2015; Vann et al., 2016).",
            "startOffset": 17406,
            "title": "Introduction"
        },
        {
            "endOffset": 30489,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "bb0015": {
                    "endOffset": 30487,
                    "startOffset": 30470
                },
                "bb0060": {
                    "endOffset": 30468,
                    "startOffset": 30446
                }
            },
            "secId": "s0065",
            "sentence": "POR activity was detected in the hepatic microsomal fractions from WT mice but not in knockout animals (Fig. 3A) which is as expected given the deletion of POR in the hepatocytes of HRN and HBRN mice (Henderson et al., 2013; Arlt et al., 2015).",
            "startOffset": 30245,
            "title": "Enzyme activity of XMEs"
        },
        {
            "endOffset": 36851,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Of the organs tested (liver, lung, kidney, small intestine, spleen, colon and bladder) only the liver, lung and small intestine exhibited any significant differences between the mouse models (Fig. 6B).",
            "startOffset": 36650,
            "title": "Ellipticine-DNA adduct formation in vivo"
        },
        {
            "endOffset": 19087,
            "parents": [],
            "refoffsets": {
                "bb0155": {
                    "endOffset": 19061,
                    "startOffset": 19039
                },
                "bb0185": {
                    "endOffset": 19085,
                    "startOffset": 19063
                }
            },
            "secId": "s0005",
            "sentence": "7-Hydroxy-ellipticine and 9-hydroxy-ellipticine are considered detoxication metabolites due to their efficient excretion by experimental animals (Stiborova et al., 2012; Stiborova et al., 2012).",
            "startOffset": 18893,
            "title": "Introduction"
        },
        {
            "endOffset": 27323,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The antigen-antibody complex was visualised using SuperSignal\u00ae West Pico Chemiluminescent Substrate Kit (Thermo Scientific).",
            "startOffset": 27199,
            "title": "Enzyme activity assays and immunoblotting"
        },
        {
            "endOffset": 44271,
            "parents": [],
            "secId": "s0085",
            "sentence": "Levels of ellipticine-DNA adduct formation were not significantly different in any of the extrahepatic organs of HBRN mice compared to WT mice, suggesting that increased levels of activated ellipticine in the extrahepatic organs could be attributed to Cyb5 activity in the HRN mice.",
            "startOffset": 43989,
            "title": "Discussion"
        },
        {
            "endOffset": 44523,
            "parents": [],
            "secId": "s0085",
            "sentence": "The significant reduction in DNA adduct formation in the livers of HRN and HBRN mice indicates that P450 enzymes are responsible for the majority of ellipticine activation, although hepatic DNA adduct formation in HRN and HBRN mice is still detectable.",
            "startOffset": 44271,
            "title": "Discussion"
        },
        {
            "endOffset": 32084,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "When EROD and Sudan I oxidation were used as a measure for Cyp1a activity hepatic microsomes from HBRN mice exhibited the lowest level of Cyp1a activity in the presence of NADH (Fig. 3B and D).",
            "startOffset": 31891,
            "title": "Enzyme activity of XMEs"
        },
        {
            "endOffset": 40802,
            "parents": [],
            "refoffsets": {
                "bb0150": {
                    "endOffset": 40800,
                    "startOffset": 40778
                },
                "bb0155": {
                    "endOffset": 40752,
                    "startOffset": 40730
                },
                "bb0185": {
                    "endOffset": 40776,
                    "startOffset": 40754
                }
            },
            "secId": "s0085",
            "sentence": "These findings were echoed in studies using human CYP3A4 in Supersomes\u2122, which found that the presence of Cyb5 in the reaction mixture also led to an increase in formation of 12-hydroxy and 13-hydroxyellipticine (Stiborova et al., 2012; Stiborova et al., 2012; Stiborova et al., 2017).",
            "startOffset": 40517,
            "title": "Discussion"
        },
        {
            "endOffset": 22950,
            "parents": [],
            "secId": "s0005",
            "sentence": "In the present study we have used both the HRN and HBRN mouse lines to investigate the contribution of Cyb5 to the metabolic activation of ellipticine to form DNA adducts in vivo alongside microsomal incubations to investigate metabolite and DNA adduct formation in vitro.",
            "startOffset": 22678,
            "title": "Introduction"
        },
        {
            "endOffset": 37671,
            "parents": [],
            "refoffsets": {
                "bb0110": {
                    "endOffset": 37669,
                    "startOffset": 37652
                }
            },
            "secId": "s0085",
            "sentence": "These mouse models have been used recently to investigate the contribution of Cyb5 in the bioactivation of BaP in vivo (Reed et al., 2018).",
            "startOffset": 37532,
            "title": "Discussion"
        },
        {
            "endOffset": 35469,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "When NADPH was used the highest ellipticine-DNA adduct formation was seen in microsomal fractions from WT mice.",
            "startOffset": 35358,
            "title": "Ellipticine-DNA adduct formation in vitro"
        },
        {
            "endOffset": 29041,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Ellipticine metabolites were extracted twice with ethyl acetate (1 ml), solvent evaporated to dryness, residues dissolved in 25 \u03bcl methanol and ellipticine metabolites separated by high performance liquid chromatography (HPLC) (5 \u03bcm Ultrasphere ODS Beckman, 4.6 mm \u00d7 250 mm preceded by a C18 guard column).",
            "startOffset": 28735,
            "title": "Microsomal incubations for studying ellipticine metabolism"
        },
        {
            "endOffset": 21106,
            "parents": [],
            "refoffsets": {
                "bb0225": {
                    "endOffset": 21104,
                    "startOffset": 21083
                },
                "bb0230": {
                    "endOffset": 20823,
                    "startOffset": 20802
                },
                "bb0235": {
                    "endOffset": 20846,
                    "startOffset": 20825
                },
                "bb0240": {
                    "endOffset": 20933,
                    "startOffset": 20915
                }
            },
            "secId": "s0005",
            "sentence": "Cyb5 can modulate P450 activity in three ways: (i) by direct transfer of both electrons via cytochrome b5 reductase (Cyb5R) in a pathway independent of POR (Yamazaki et al., 1996; Yamazaki et al., 1996); (ii) by transfer of the second electron from either POR or Cyb5R (Zhang et al., 2007); or (iii) by acting as an allosteric modifier of the enzyme in a non-catalytic role that can enhance reactions for many, but not all, P450 enzymes (Yamazaki et al., 2002).",
            "startOffset": 20645,
            "title": "Introduction"
        },
        {
            "endOffset": 43791,
            "parents": [],
            "secId": "s0085",
            "sentence": "In the present study there was a trend for ellipticine-DNA adduct levels to be higher in the extrahepatic organs, i.e. kidney, colon and bladder, of both HRN and HBRN mice compared to WT mice, with levels of ellipticine-DNA adduct formation being significantly higher in the lungs and small intestines of HRN mice compared to WT mice.",
            "startOffset": 43457,
            "title": "Discussion"
        },
        {
            "endOffset": 25753,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Protein concentration in the microsomal fraction was measured using the bicinchoninic acid protein assay with bovine serum albumin as standard.",
            "startOffset": 25610,
            "title": "Preparation of microsomes"
        },
        {
            "endOffset": 44750,
            "parents": [],
            "secId": "s0085",
            "sentence": "It is possible that ellipticine activation still occurs due to the greater induction of hepatic P450 enzymes in HRN and HBRN mice compared to WT mice combined with expression of POR and Cyb5 in the non-parenchymal liver cells.",
            "startOffset": 44524,
            "title": "Discussion"
        },
        {
            "endOffset": 22677,
            "parents": [],
            "refoffsets": {
                "bb0055": {
                    "endOffset": 22559,
                    "startOffset": 22537
                },
                "bb0060": {
                    "endOffset": 22675,
                    "startOffset": 22653
                }
            },
            "secId": "s0005",
            "sentence": "Hepatic Cytochrome b5/P450 Reductase Null (HBRN) mice (Henderson et al., 2014) lack both POR and Cyb5 in their livers and have reduced P450 activity relative to HRN mice (Henderson et al., 2013).",
            "startOffset": 22482,
            "title": "Introduction"
        },
        {
            "endOffset": 27805,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Reduced nicotinamide adenine dinucleotide (NADPH) or reduced form of nicotinamide adenine dinucleotide (NADH) (10 mM in each case), pooled hepatic microsomal fraction (0.5 mg/ml protein) from ellipticine-pretreated HRN, HBRN and WT mice, 0.1 mM ellipticine dissolved in 7.5 \u03bcl methanol and calf thymus DNA (0.5 mg) in a final volume of 750 \u03bcl.",
            "startOffset": 27462,
            "title": "Microsomal incubations for ellipticine-DNA adduct formation"
        },
        {
            "endOffset": 30219,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Cyp3a protein is constitutively expressed across all mouse lines but expression was increased in HRN and HBRN mice.",
            "startOffset": 30104,
            "title": "Protein expression of XMEs"
        },
        {
            "endOffset": 19220,
            "parents": [],
            "secId": "s0005",
            "sentence": "Therefore, understanding the role of P450 enzymes in ellipticine metabolism is important both pharmacologically and toxicologically.",
            "startOffset": 19088,
            "title": "Introduction"
        },
        {
            "endOffset": 30713,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "We used Sudan I oxidation (Fig. 3B), MROD (Fig. 3C) and EROD (Fig. 3D) as measures of Cyp1a1, Cyp1a2 and Cyp1a enzyme activity, respectively, and testosterone 6\u03b2-hydroxylation (Fig. 3E) as a measure of Cyp3a enzyme activity.",
            "startOffset": 30489,
            "title": "Enzyme activity of XMEs"
        },
        {
            "endOffset": 32905,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "No metabolites were detected in control incubations without microsomes, without NADPH/NADH-generating system or without ellipticine (Fig. 4C and D).",
            "startOffset": 32757,
            "title": "HPLC analysis of ellipticine metabolites"
        },
        {
            "endOffset": 39797,
            "parents": [],
            "secId": "s0085",
            "sentence": "Although this reduction in total metabolite formation would be suggestive of the contribution of Cyb5 to the activation of ellipticine, whilst all metabolites formed by HBRN fractions were reduced compared to WT, the only metabolite significantly reduced in HBRN fractions compared to HRN fractions was 9-hydroxyellipticine, a detoxication metabolite.",
            "startOffset": 39446,
            "title": "Discussion"
        },
        {
            "endOffset": 29976,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Cyb5R was expressed uniformly across all mouse lines.",
            "startOffset": 29923,
            "title": "Protein expression of XMEs"
        },
        {
            "endOffset": 28524,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Incubations were carried out at 37 \u00b0C for 20 min.",
            "startOffset": 28475,
            "title": "Microsomal incubations for studying ellipticine metabolism"
        },
        {
            "endOffset": 43988,
            "parents": [],
            "secId": "s0085",
            "sentence": "This could be due to the decreased levels of P450-mediated ellipticine metabolism in the livers of HRN and HBRN mice causing higher amounts of ellipticine to be distributed to extrahepatic organs.",
            "startOffset": 43792,
            "title": "Discussion"
        },
        {
            "endOffset": 39980,
            "parents": [],
            "refoffsets": {
                "bb0115": {
                    "endOffset": 39978,
                    "startOffset": 39956
                }
            },
            "secId": "s0085",
            "sentence": "This supports previous results in the HRN mouse with 9-hydroxyellipticine being affected by the absence of POR and P450 activity more than other metabolites (Stiborova et al., 2008).",
            "startOffset": 39798,
            "title": "Discussion"
        },
        {
            "endOffset": 27198,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The secondary horseradish peroxidase-linked antibodies were as follows: anti-goat 1:10000 (sc-2020, Santa Cruz) anti-rabbit 1:10000 (#170\u20135046, BioRad).",
            "startOffset": 27046,
            "title": "Enzyme activity assays and immunoblotting"
        },
        {
            "endOffset": 38852,
            "parents": [],
            "secId": "s0085",
            "sentence": "However, whilst significant reductions in total ellipticine metabolite and ellipticine-DNA adduct formation were found compared to WT there was no significant difference between HRN and HBRN fractions themselves, correlating with the results from Cyp3a marker activity.",
            "startOffset": 38583,
            "title": "Discussion"
        },
        {
            "endOffset": 41327,
            "parents": [],
            "secId": "s0085",
            "sentence": "In the hepatic microsomal fractions from HRN mice in the presence of NADH, however, the formation of 9-hydroxyellipticine was significantly higher than with microsomal fractions from WT mice whilst metabolites associated with metabolic activation were significantly lower (i.e. 12-hydroxyellipticine).",
            "startOffset": 41026,
            "title": "Discussion"
        },
        {
            "endOffset": 23038,
            "parents": [],
            "secId": "s0005",
            "sentence": "Hepatic microsomal P450 enzyme activity and protein expression have also been assessed.",
            "startOffset": 22951,
            "title": "Introduction"
        },
        {
            "endOffset": 46520,
            "parents": [],
            "refoffsets": {
                "bb0190": {
                    "endOffset": 46471,
                    "startOffset": 46449
                }
            },
            "secId": "s0085",
            "sentence": "Peroxidase-mediated ellipticine activation was also shown to generate two additional DNA adducts (Stiborova et al., 2007) that were, however, not detected in this study.",
            "startOffset": 46351,
            "title": "Discussion"
        },
        {
            "endOffset": 32284,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "When NADH was used in the reaction mixture, hepatic microsomes from HRN mice showed significantly higher Cyp3a activity than the hepatic microsomal fractions from HBRN mice but not WT mice (Fig. 3E).",
            "startOffset": 32085,
            "title": "Enzyme activity of XMEs"
        },
        {
            "endOffset": 35251,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "bb0115": {
                    "endOffset": 35201,
                    "startOffset": 35179
                },
                "bb0155": {
                    "endOffset": 35225,
                    "startOffset": 35203
                },
                "bb0185": {
                    "endOffset": 35249,
                    "startOffset": 35227
                }
            },
            "secId": "s0075",
            "sentence": "The ellipticine-DNA adduct pattern obtained by 32P-postlabelling analysis from microsomal incubations consisted of one major and one minor adduct spot (Fig. 6A insert) (assigned adduct 1 and 2) previously detected in vitro and in vivo (Stiborova et al., 2008; Stiborova et al., 2012; Stiborova et al., 2012).",
            "startOffset": 34943,
            "title": "Ellipticine-DNA adduct formation in vitro"
        },
        {
            "endOffset": 28640,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Control incubations were carried out (i) without microsomes; (ii) without NADPH or NADH; (iii) without ellipticine.",
            "startOffset": 28525,
            "title": "Microsomal incubations for studying ellipticine metabolism"
        },
        {
            "endOffset": 36450,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "bb0115": {
                    "endOffset": 36348,
                    "startOffset": 36326
                },
                "bb0130": {
                    "endOffset": 36300,
                    "startOffset": 36278
                },
                "bb0165": {
                    "endOffset": 36372,
                    "startOffset": 36350
                },
                "bb0195": {
                    "endOffset": 36324,
                    "startOffset": 36302
                }
            },
            "secId": "s0080",
            "sentence": "Another adduct, tentative assigned adduct spot 4, which was previously detected in ellipticine-treated rats and mice (Stiborova et al., 2003; Stiborova et al., 2007; Stiborova et al., 2008; Stiborova et al., 2014), was also generated in WT and HRN mice in selected tissues (Fig. 6B insert).",
            "startOffset": 36160,
            "title": "Ellipticine-DNA adduct formation in vivo"
        },
        {
            "endOffset": 33899,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "All metabolites were detected at significantly lower amounts compared to WT hepatic microsomes and 9-hydroxyellipticine was lower compared to HRN hepatic microsomes (Fig. 5A).",
            "startOffset": 33724,
            "title": "HPLC analysis of ellipticine metabolites"
        },
        {
            "endOffset": 47818,
            "parents": [],
            "secId": "s0085",
            "sentence": "These findings confirm the importance of P450 enzymes in the bioactivation of ellipticine.",
            "startOffset": 47728,
            "title": "Discussion"
        },
        {
            "endOffset": 45143,
            "parents": [],
            "secId": "s0085",
            "sentence": "The bioactivation of ellipticine can also be catalysed via P450-independent mechanisms that are not dependent on POR or Cyb5.",
            "startOffset": 45018,
            "title": "Discussion"
        },
        {
            "endOffset": 41712,
            "parents": [],
            "secId": "s0085",
            "sentence": "This correlation, however, does appear to be limited to ellipticine metabolite formation.",
            "startOffset": 41623,
            "title": "Discussion"
        },
        {
            "endOffset": 24329,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Ellipticine was administered dissolved in 1% acetic acid at a concentration of 2.5 mg/ml.",
            "startOffset": 24240,
            "title": "Animal treatment"
        },
        {
            "endOffset": 41025,
            "parents": [],
            "secId": "s0085",
            "sentence": "In the present study we found that hepatic microsomal fractions from HBRN mice that do not possess either electron donor, metabolite formation was significantly lower than with WT fractions regardless of the cofactor used.",
            "startOffset": 40803,
            "title": "Discussion"
        },
        {
            "endOffset": 18705,
            "parents": [],
            "refoffsets": {
                "bb0010": {
                    "endOffset": 18629,
                    "startOffset": 18610
                },
                "bb0140": {
                    "endOffset": 18653,
                    "startOffset": 18631
                },
                "bb0145": {
                    "endOffset": 18679,
                    "startOffset": 18655
                },
                "bb0165": {
                    "endOffset": 18703,
                    "startOffset": 18681
                },
                "bb0205": {
                    "endOffset": 18608,
                    "startOffset": 18586
                }
            },
            "secId": "s0005",
            "sentence": "As shown in Fig. 1, ellipticine is oxidised by P450 enzymes to form five metabolites, including the reactive metabolites 12-hydroxy- and 13-hydroxy-ellipticine which dissociate to ellipticine-12-ylium and ellipticine-13-ylium and bind to DNA (Stiborova et al., 2004; Aimova et al., 2007; Stiborova et al., 2014; Stiborova and Frei, 2014; Stiborova et al., 2014).",
            "startOffset": 18343,
            "title": "Introduction"
        },
        {
            "endOffset": 24383,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Control mice (n = 3/group) received the solvent only.",
            "startOffset": 24330,
            "title": "Animal treatment"
        },
        {
            "endOffset": 46350,
            "parents": [],
            "secId": "s0085",
            "sentence": "However, the structure of this adduct has not yet been elucidated.",
            "startOffset": 46284,
            "title": "Discussion"
        },
        {
            "endOffset": 47276,
            "parents": [],
            "refoffsets": {
                "bb0135": {
                    "endOffset": 47274,
                    "startOffset": 47252
                }
            },
            "secId": "s0085",
            "sentence": "In the hepatic microsomal fractions from mice pretreated with BaP, ellipticine-DNA adduct formation with arachidonic acid was higher, very likely due to induction of COX by BaP, with no significant difference between fractions from WT and HRN mice (Stiborova et al., 2013).",
            "startOffset": 47003,
            "title": "Discussion"
        },
        {
            "endOffset": 47613,
            "parents": [],
            "secId": "s0085",
            "sentence": "In summary, this study has shown that whilst POR contributes to the bioactivation of ellipticine in vitro, the role of Cyb5 is still rather unclear.",
            "startOffset": 47465,
            "title": "Discussion"
        },
        {
            "endOffset": 19951,
            "parents": [],
            "refoffsets": {
                "bb0065": {
                    "endOffset": 19949,
                    "startOffset": 19927
                }
            },
            "secId": "s0005",
            "sentence": "HRN mice have a deletion of NADPH:cytochrome P450 oxidoreductase (POR), the predominant electron donor to P450s, specifically in their hepatocytes (Henderson et al., 2003).",
            "startOffset": 19779,
            "title": "Introduction"
        },
        {
            "endOffset": 35753,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "The degree of total ellipticine-DNA adduct formation in the hepatic microsomal fractions correlated with the amounts of ellipticine metabolites formed (compare Fig. 5A).",
            "startOffset": 35584,
            "title": "Ellipticine-DNA adduct formation in vitro"
        },
        {
            "endOffset": 46739,
            "parents": [],
            "refoffsets": {
                "bb0135": {
                    "endOffset": 46737,
                    "startOffset": 46715
                }
            },
            "secId": "s0085",
            "sentence": "Studies with hepatic microsomal fractions from WT and HRN mice from mice pretreated with BaP were carried out to investigate the effect of enzyme induction on activation of ellipticine in vitro (Stiborova et al., 2013).",
            "startOffset": 46520,
            "title": "Discussion"
        },
        {
            "endOffset": 24962,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bb0115": {
                    "endOffset": 24939,
                    "startOffset": 24917
                },
                "bb0220": {
                    "endOffset": 24960,
                    "startOffset": 24941
                }
            },
            "secId": "s0025",
            "sentence": "Genomic DNA from whole tissue was isolated by a standard phenol-chloroform extraction method and DNA adducts were measured for each DNA sample using the nuclease P1 enrichment version of the thin-layer chromatography (TLC)-32P-postlabelling method as described previously (Stiborova et al., 2008; Willis et al., 2018).",
            "startOffset": 24644,
            "title": "Ellipticine-DNA adduct detection by 32P-postlabelling analysis"
        },
        {
            "endOffset": 17804,
            "parents": [],
            "secId": "s0005",
            "sentence": "Ellipticine needs to be metabolised to exert its pharmacological effects.",
            "startOffset": 17731,
            "title": "Introduction"
        },
        {
            "endOffset": 26555,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bb0110": {
                    "endOffset": 26553,
                    "startOffset": 26536
                }
            },
            "secId": "s0035",
            "sentence": "Western blotting analysis using 4\u201312% Bis-Tris gradient gels and sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) were carried out as described previously (Reed et al., 2018).",
            "startOffset": 26359,
            "title": "Enzyme activity assays and immunoblotting"
        },
        {
            "endOffset": 20471,
            "parents": [],
            "refoffsets": {
                "bb0115": {
                    "endOffset": 20469,
                    "startOffset": 20447
                }
            },
            "secId": "s0005",
            "sentence": "HRN mice formed 65% lower levels of ellipticine-DNA adducts in their livers than wild-type (WT) mice, demonstrating the importance of P450 activity in the hepatic bioactivation of ellipticine (Stiborova et al., 2008).",
            "startOffset": 20254,
            "title": "Introduction"
        },
        {
            "endOffset": 29779,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Expression of electron donor proteins (i.e. POR, Cyb5, Cyb5R) associated with the mixed-function oxidase system (i.e. P450) were probed for in the hepatic microsomal fractions from WT, HRN and HBRN mice exposed to ellipticine (Fig. 2).",
            "startOffset": 29544,
            "title": "Protein expression of XMEs"
        },
        {
            "endOffset": 31197,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "According to the Sudan I oxidation and MROD assays Cyp1a1/2 activity was significantly lower in the hepatic microsomes from HRN mice which correlated with the lack of POR activity in HRN mice relative to WT mice.",
            "startOffset": 30985,
            "title": "Enzyme activity of XMEs"
        },
        {
            "endOffset": 48095,
            "parents": [],
            "secId": "s0085",
            "sentence": "Whilst non-parenchymal liver cells may play a role in catalysing P450-mediated bioactivation of ellipticine in HRN and HBRN mice, the presence of ellipticine-DNA adducts in the livers of HRN and HBRN mice suggests the involvement of a P450-independent bioactivation mechanism.",
            "startOffset": 47819,
            "title": "Discussion"
        },
        {
            "endOffset": 23341,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Testosterone and 6\u03b2-hydroxytestosterone were purchased from Merck (Darmstadt, Germany).",
            "startOffset": 23254,
            "title": "Chemicals"
        },
        {
            "endOffset": 34551,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "The overall metabolite formation in hepatic fractions from HBRN mice was significantly lower than with both WT and HRN fractions (Fig. 5B) with 9-hydroxyellipticine being significantly lower compared with both WT and HRN fractions and 12-hydroxyellipticine being significantly lower compared with WT (Fig. 5B).",
            "startOffset": 34241,
            "title": "HPLC analysis of ellipticine metabolites"
        },
        {
            "endOffset": 30103,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Cyp1a1 protein expression was greater in HRN and HBRN hepatic microsomal fractions after ellipticine treatment compared to WT.",
            "startOffset": 29977,
            "title": "Protein expression of XMEs"
        },
        {
            "endOffset": 20644,
            "parents": [],
            "refoffsets": {
                "bb0045": {
                    "endOffset": 20642,
                    "startOffset": 20625
                },
                "bb0225": {
                    "endOffset": 20623,
                    "startOffset": 20602
                }
            },
            "secId": "s0005",
            "sentence": "Although POR is viewed as the predominant electron donor to P450 enzymes, cytochrome b5 (Cyb5) can also act as the electron donor (Yamazaki et al., 2002; Finn et al., 2008).",
            "startOffset": 20471,
            "title": "Introduction"
        },
        {
            "endOffset": 19657,
            "parents": [],
            "secId": "s0005",
            "sentence": "However, due to the large number of CYP enzymes it has been difficult to determine the in vivo role of P450 enzymes as a whole as there are overlapping substrate specificities.",
            "startOffset": 19481,
            "title": "Introduction"
        },
        {
            "endOffset": 19480,
            "parents": [],
            "refoffsets": {
                "bb0095": {
                    "endOffset": 19459,
                    "startOffset": 19440
                },
                "bb0105": {
                    "endOffset": 19478,
                    "startOffset": 19461
                },
                "bb0160": {
                    "endOffset": 19438,
                    "startOffset": 19416
                }
            },
            "secId": "s0005",
            "sentence": "A number of transgenic mouse lines (e.g. CYP-knockout or CYP-humanised) have been applied to study the contribution of individual P450 enzymes to chemical-induced genotoxicity and carcinogenesis (Stiborova et al., 2012; Nebert et al., 2013; Reed et al., 2018).",
            "startOffset": 19220,
            "title": "Introduction"
        },
        {
            "endOffset": 21847,
            "parents": [],
            "refoffsets": {
                "bb0075": {
                    "endOffset": 21821,
                    "startOffset": 21800
                },
                "bb0155": {
                    "endOffset": 21845,
                    "startOffset": 21823
                }
            },
            "secId": "s0005",
            "sentence": "The formation of ellipticine-DNA adducts was also shown to increase ~6-fold in the case of CYP1A1, ~4-fold for CYP1A2 and ~3-fold for CYP3A4 (Kotrbova et al., 2011; Stiborova et al., 2012).",
            "startOffset": 21658,
            "title": "Introduction"
        },
        {
            "endOffset": 28189,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Ellipticine-DNA adduct formation was determined by 32P-postlabelling as described above.",
            "startOffset": 28101,
            "title": "Microsomal incubations for ellipticine-DNA adduct formation"
        },
        {
            "endOffset": 36649,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "As this adduct was only detectable in a few tissues (liver, lung and small intestine) in WT and HRN mice but not HBRN its level was not quantified when adduct formation was compared between tissues.",
            "startOffset": 36451,
            "title": "Ellipticine-DNA adduct formation in vivo"
        },
        {
            "endOffset": 42278,
            "parents": [],
            "secId": "s0085",
            "sentence": "The present in vivo results correlated with in vitro ellipticine-DNA adduct formation when NADPH was used as cofactor.",
            "startOffset": 42160,
            "title": "Discussion"
        },
        {
            "endOffset": 38582,
            "parents": [],
            "secId": "s0085",
            "sentence": "When NADPH was used as cofactor to examine the POR-dependent pathway, P450 enzyme activity assays clearly showed a reduction in Cyp1a activity as electron donors were lost.",
            "startOffset": 38410,
            "title": "Discussion"
        },
        {
            "endOffset": 34240,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "When NADH was used as cofactor the overall formation of metabolites in hepatic microsomal fractions from HRN mice was not significantly different to fractions from WT with 9-hydroxyellipticine being significantly higher but 12-hydroxyellipticine being significantly lower and no significant difference in the levels of 13-hydroxyellipticine.",
            "startOffset": 33899,
            "title": "HPLC analysis of ellipticine metabolites"
        },
        {
            "endOffset": 36159,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "bb0115": {
                    "endOffset": 36109,
                    "startOffset": 36087
                },
                "bb0155": {
                    "endOffset": 36133,
                    "startOffset": 36111
                },
                "bb0185": {
                    "endOffset": 36157,
                    "startOffset": 36135
                }
            },
            "secId": "s0080",
            "sentence": "The ellipticine-DNA adduct pattern obtained from in vivo treatments consisted of one major adduct spot (assigned adduct 1 in Fig. 6B) previously detected in vitro and in vivo (Stiborova et al., 2008; Stiborova et al., 2012; Stiborova et al., 2012).",
            "startOffset": 35911,
            "title": "Ellipticine-DNA adduct formation in vivo"
        },
        {
            "endOffset": 41946,
            "parents": [],
            "refoffsets": {
                "bb0075": {
                    "endOffset": 41776,
                    "startOffset": 41755
                },
                "bb0100": {
                    "endOffset": 41753,
                    "startOffset": 41731
                },
                "bb0135": {
                    "endOffset": 41800,
                    "startOffset": 41778
                },
                "bb0150": {
                    "endOffset": 41824,
                    "startOffset": 41802
                }
            },
            "secId": "s0085",
            "sentence": "Previous studies (Poljakova et al., 2005; Kotrbova et al., 2011; Stiborova et al., 2013; Stiborova et al., 2017) found that the shift in metabolite production was coupled with an increase in in vitro ellipticine-DNA adduct formation.",
            "startOffset": 41713,
            "title": "Discussion"
        },
        {
            "endOffset": 32756,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Three metabolites were formed in the microsomal incubations; 9-hydroxyellipticine (assigned peak M1), 12-hydroxyellipticine (assigned peak M2) and 13-hydroxyellipticine (assigned peak M3) (Fig. 4A and B).",
            "startOffset": 32552,
            "title": "HPLC analysis of ellipticine metabolites"
        },
        {
            "endOffset": 37531,
            "parents": [],
            "secId": "s0085",
            "sentence": "In the present study we have used both HRN mice, which lack expression of hepatic POR, and HBRN mice, which lack expression of hepatic POR and Cyb5, to investigate the contribution of Cyb5 to the metabolic activation of ellipticine in vivo.",
            "startOffset": 37291,
            "title": "Discussion"
        },
        {
            "endOffset": 47465,
            "parents": [],
            "secId": "s0085",
            "sentence": "This participation of COX in hepatic microsomal fractions from HRN mice suggests that peroxidases could be responsible for the activation of ellipticine in the livers of HRN and HBRN mice.",
            "startOffset": 47277,
            "title": "Discussion"
        },
        {
            "endOffset": 23924,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Animals were maintained in open-top cages, with free access to food (RM1 diet, Special Diet Services, Essex, UK) and water, and a 12-h light/dark cycle.",
            "startOffset": 23772,
            "title": "Animal treatment"
        },
        {
            "endOffset": 35868,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "When NADH was used there was no significant difference in adduct formation between any of the fractions (Fig. 6A).",
            "startOffset": 35754,
            "title": "Ellipticine-DNA adduct formation in vitro"
        },
        {
            "endOffset": 22482,
            "parents": [],
            "secId": "s0005",
            "sentence": "Together these studies provide evidence for the role of Cyb5 in the bioactivation of ellipticine both in vitro and in vivo.",
            "startOffset": 22359,
            "title": "Introduction"
        },
        {
            "endOffset": 19778,
            "parents": [],
            "refoffsets": {
                "bb0015": {
                    "endOffset": 19776,
                    "startOffset": 19759
                }
            },
            "secId": "s0005",
            "sentence": "We have used the Hepatic P450 Reductase Null (HRN) mouse model in order to overcome this limitation (Arlt et al., 2015).",
            "startOffset": 19658,
            "title": "Introduction"
        },
        {
            "endOffset": 41622,
            "parents": [],
            "refoffsets": {
                "bb0075": {
                    "endOffset": 41548,
                    "startOffset": 41527
                },
                "bb0150": {
                    "endOffset": 41620,
                    "startOffset": 41598
                },
                "bb0155": {
                    "endOffset": 41572,
                    "startOffset": 41550
                },
                "bb0185": {
                    "endOffset": 41596,
                    "startOffset": 41574
                }
            },
            "secId": "s0085",
            "sentence": "The absence of Cyb5 in hepatic microsomal fractions from HBRN mice correlates with the findings from reconstituted P450 enzymes suggesting Cyb5 contributes to the activation of ellipticine in vitro (Kotrbova et al., 2011; Stiborova et al., 2012; Stiborova et al., 2012; Stiborova et al., 2017).",
            "startOffset": 41328,
            "title": "Discussion"
        },
        {
            "endOffset": 42717,
            "parents": [],
            "refoffsets": {
                "bb0115": {
                    "endOffset": 42608,
                    "startOffset": 42586
                }
            },
            "secId": "s0085",
            "sentence": "The HRN results correlate with a previous study that found a 65% reduction in hepatic DNA adduct formation in HRN mice (Stiborova et al., 2008) suggesting a greater contribution of the POR-dependent pathway to the bioactivation of ellipticine in vivo.",
            "startOffset": 42466,
            "title": "Discussion"
        },
        {
            "endOffset": 23771,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bb0060": {
                    "endOffset": 23769,
                    "startOffset": 23747
                },
                "bb0065": {
                    "endOffset": 23745,
                    "startOffset": 23723
                }
            },
            "secId": "s0020",
            "sentence": "HRN (Porlox/lox/CreCYP1A1) mice and HBRN (Cytb5lox/lox/Porlox/lox \u00b1 CreALB) mice on a C57BL/6 background were derived as described previously (Henderson et al., 2003; Henderson et al., 2013).",
            "startOffset": 23580,
            "title": "Animal treatment"
        },
        {
            "endOffset": 46283,
            "parents": [],
            "refoffsets": {
                "bb0130": {
                    "endOffset": 46103,
                    "startOffset": 46081
                },
                "bb0165": {
                    "endOffset": 46151,
                    "startOffset": 46129
                },
                "bb0195": {
                    "endOffset": 46127,
                    "startOffset": 46105
                },
                "bb0200": {
                    "endOffset": 46281,
                    "startOffset": 46259
                }
            },
            "secId": "s0085",
            "sentence": "In several tissues in ellipticine-treated WT and HRN mice (present study) we detected adduct 4 which previously has also been observed in ellipticine-treated rats (Stiborova et al., 2003; Stiborova et al., 2007; Stiborova et al., 2014) and in vitro studying ellipticine-DNA adduct formation recombinant human CYP3A4 expressed in Supersomes\u2122 (Stiborova et al., 2011).",
            "startOffset": 45917,
            "title": "Discussion"
        },
        {
            "endOffset": 31786,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "When the cofactor for Cyb5R, NADH, was used in the reaction mixture, hepatic microsomes from HRN mice showed significantly higher Cyp1a activity than the hepatic microsomal fractions from WT and HBRN mice (Fig. 3B-D).",
            "startOffset": 31569,
            "title": "Enzyme activity of XMEs"
        },
        {
            "endOffset": 33295,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Hydroxylated ellipticine metabolites were identified and the structures are shown in Fig. 1.",
            "startOffset": 33203,
            "title": "HPLC analysis of ellipticine metabolites"
        },
        {
            "endOffset": 32551,
            "parents": [
                {
                    "id": "s0055",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Representative HPLC chromatograms are shown in Fig. 4.",
            "startOffset": 32497,
            "title": "HPLC analysis of ellipticine metabolites"
        }
    ],
    "docId": "S0041008X19300341",
    "metadata": {
        "asjc": [
            "3004",
            "3005"
        ],
        "authors": [
            {
                "email": null,
                "first": "Lindsay",
                "initial": "L.",
                "last": "Reed"
            },
            {
                "email": null,
                "first": "Radek",
                "initial": "R.",
                "last": "Indra"
            },
            {
                "email": null,
                "first": "Iveta",
                "initial": "I.",
                "last": "Mrizova"
            },
            {
                "email": null,
                "first": "Michaela",
                "initial": "M.",
                "last": "Moserova"
            },
            {
                "email": null,
                "first": "Heinz H.",
                "initial": "H.H.",
                "last": "Schmeiser"
            },
            {
                "email": null,
                "first": "C. Roland",
                "initial": "C.R.",
                "last": "Wolf"
            },
            {
                "email": null,
                "first": "Colin J.",
                "initial": "C.J.",
                "last": "Henderson"
            },
            {
                "email": null,
                "first": "Marie",
                "initial": "M.",
                "last": "Stiborova"
            },
            {
                "email": null,
                "first": "David H.",
                "initial": "D.H.",
                "last": "Phillips"
            },
            {
                "email": "volker.arlt@kcl.ac.uk",
                "first": "Volker M.",
                "initial": "V.M.",
                "last": "Arlt"
            }
        ],
        "doi": "10.1016/j.taap.2019.01.020",
        "firstpage": "64",
        "issn": "0041008X",
        "keywords": [
            " Cytochrome b 5",
            "Cytochrome P450",
            "DNA Adducts",
            "Metabolism",
            "Mouse models"
        ],
        "lastpage": "74",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "PHAR"
        ],
        "title": " Application of hepatic cytochrome b 5 /P450 reductase null (HBRN) mice to study the role of cytochrome b 5 in the cytochrome P450-mediated bioactivation of the anticancer drug ellipticine "
    }
}